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Schizophrenia is a devastating psychiatric condition marked by severe cognitive 
impairments, brain anatomy alterations, and abnormal neurotransmitter activity. This study 
examines whether the genetically modified GCPII+/- mouse model, which has reduced glutamate 
carboxypeptidase II (GCPII) enzyme activity to mimic the hypoglutamatergic pathways observed 
in schizophrenia, creates magnetic resonance-detectable alterations in morphology and/or 
neurochemistry that can be used for studies of potential treatments. The longitudinal portion of 
this study employs the non-invasive techniques of magnetic resonance imaging (MRI) and 
spectroscopy (MRS). Data were collected from 4 male and 7 female heterozygous GCPII+/- 
(HET) and 6 male and 7 female normal (wild-type; WT) mice on postnatal days (PND) 35/36, 
49/50 and 63/64. MRI was used to examine the volumes of the brain structures affected by 
schizophrenia in humans. MRS was used to measure neurometabolite concentrations in the 
hippocampus, a brain structure known to function differently in schizophrenia. We hypothesized 
that the brain morphology and metabolite concentrations between HET and WT mice would 
differ and that HET mice would mirror characteristics found in human schizophrenia patients. If 
reduced GCPII function could replicate neurological symptoms of schizophrenia, then the 
GCPII+/-model would be a promising tool for treatment studies that target the glutamatergic 
pathways of schizophrenia.  
MRI data revealed enlarged third, fourth, and lateral ventricles, and asymmetric 
hippocampi in HET mice compared to WT mice. These findings are characteristic of 
schizophrenia patients. MRS data showed apparent differences in (N-acetylaspartate + N-
acetylaspartylglutamate)/ creatine (Cr) levels, but no significant effect of genotype on (N-
acetylaspartate + N-acetylaspartylglutamate)/Cr, choline/Cr, taurine/Cr, or (glutamate + 
glutamine)/Cr ratios. Sex differences were found in cerebellum to WBV ratios of HET and WT 
mice, and hippocampus asymmetry and choline/Cr levels in HET mice. These data are consistent 
with findings on schizophrenia patients and suggest that the GCPII+/- mouse model may be a 
good mouse model for schizophrenia treatment development. However, more research must be 
conducted to increase the sample size of data and further characterize the GCPII+/- mouse model.  
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Schizophrenia is a severe mental disorder whose treatments are limited as they only 
partially relieve symptoms (Jones et al. 2011; Nasrallah et al., 2011; Trivedi and Jarbe, 2011). 
This thesis investigates a genetically modified mouse (GCPII+/-) that has reduced GCPII enzyme 
activity to replicate the hypoglutamatergic activity suspected in schizophrenia patients. The goal 
of this developmental study was to characterize the GCPII+/- mouse model and to investigate sex 
differences using magnetic resonance techniques. If the GCPII+/- mouse model replicates the 
pathophysiology and neurological symptoms of schizophrenia then the model would be a 
promising tool for treatment studies that target the glutamatergic pathways of schizophrenia.  
1 Introduction 
 
Schizophrenia is a disabling and chronic mental disorder that affects the most complex 
functions of the brain. The onset of schizophrenia occurs in young adulthood, but the disorder 
persists chronically and can cause a lifetime of suffering for the diagnosed individual and their 
family members. Women and men are affected equally, however women often exhibit symptoms 
later than men and in a milder form (Vorvick, 2010). Those with schizophrenia tend to have a 
shorter life expectancy by approximately 12-15 years as compared to the average population – a 
gap that has been increasing (van Os and Kapur, 2009). Physical causes are responsible for most 
deaths and result from decreased access to medical care and increased frequency of routine risk 
factors – such as a poor diet and smoking (van Os and Kapur, 2009). Though schizophrenia has a 
prevalence of about 1% in the world population, little is known about the disorder and current 
treatments are inadequate, as they can only partially relieve symptoms (Jones et al. 2011; 
Nasrallah et al., 2011; Trivedi and Jarbe, 2011). 
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Schizophrenia’s multitude of symptoms makes diagnosis difficult because individual 
symptoms can be associated with other mental illnesses (van Os and Kapur, 2009). Symptoms of 
schizophrenia are categorized into three categories: positive, negative, and cognitive. Positive 
symptoms reflect an excess or distortion of normal functions and include characteristics 
commonly associated with schizophrenia, such as delusions and hallucinations. Negative 
symptoms refer to diminished characteristics of normal function and include depression, lack of 
emotion, and social withdrawal. Cognitive symptoms involve thought processes and include 
difficulties in memory, attention, and making sense of information (Andreason, 2000; Wilson 
and Terry, 2010). Current treatment options can only alleviate positive symptoms (Nasrallah et 
al., 2011).  
Research on the etiology of schizophrenia suggests that genetic factors play a role as the 
offspring of those with schizophrenia have a higher likelihood of also being diagnosed compared 
to controls (van Os and Kapur, 2009). However, no single genetic alteration is responsible for 
schizophrenia (Jones et al., 2011). Certain environmental factors, such as prenatal exposures or 
social stress have also been linked to an increased risk of developing schizophrenia. These 
factors disrupt neural development, resulting in subtle changes of specific neurons and circuits, 
which may then lead to neurological malfunction (Lieberman et al., 2002). Altered levels of 
certain naturally occurring brain chemicals, including the neurotransmitters dopamine and 
glutamate, support the neurochemical basis of schizophrenia (Lieberman et al., 2002).  
1.1  Dopamine Hypothesis 
The first and most enduring neurochemically-based hypothesis suggests that the central 
pathophysiology of schizophrenia arises from dopamine dysfunction in the limbic system, an 
area in the brain associated with learning, memory, and emotional response (Figure 1-1). The 
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limbic system is known to be overactive in schizophrenia. Two major clinical observations 
provided evidence for the dopamine hypothesis – (1) schizophrenic-like symptoms occur in 
people who use amphetamine, a drug that causes excessive dopamine release and (2) dopamine 
antagonists resulted in alleviation of the positive symptoms of schizophrenia (Howes and Kapur, 
2009; Konradi and Hecker, 2003). Though promising, this hypothesis is incomplete as patients 
who took dopamine antagonists still suffered from the disabling cognitive and motivational 
impairments of negative symptoms (van Os and Kapur, 2009). Thus researchers developed new 
hypotheses involving other neurotransmitters such as glutamate. 
 
Figure 1-1. Cartoon of a human brain with the structures of the limbic system 
labeled by color. The main role of each structure is indicated in parentheses. 
Adapted from University of Colorado (2008). 
 4 
1.2  Glutamate Hypothesis  
 
 
Glutamate is the primary neurotransmitter in the mammalian brain and a key regulator of 
inhibition. When glutamate activates N-methyl-D-aspartate receptors (NMDAR) on inhibitory 
neurons, synaptic activity to the limbic system is inhibited (Figure 1-2; Olney et al., 1999).  The 
glutamate hypothesis suggests that schizophrenia is caused by hypoactivity of glutamate due to 
hypofunction of NMDAR in the frontal lobe (Coyle, 2006; Han et al., 2009; Olney et al., 1999). 
If NMDAR function is reduced, then there would be increased limbic system activity, a 
characteristic of schizophrenia. This hypothesis was formulated when it was determined that 
hallucinogenic drugs that block signals in the brain and reduce the perception of pain, called 
dissociative anesthetics, such as phencyclidine (PCP) and ketamine induced positive, negative, 
and cognitive symptoms similar to those of schizophrenia (Moghaddam and Javitt, 2011). The 
discovery that these compounds function by blocking the NMDAR channel was key to the 
generation of the hypothesis that hypofunction of NMDAR, not hyperactivity of dopamine, may 
contribute to the pathophysiology of schizophrenia (Coyle, 2006; Olney et al., 1999). When 
NMDAR are blocked, there is an excessive release of glutamate and acetylcholine. Olney et al. 
Figure 1-2. Interaction of dopamine and glutamate pathways. Dopamine 
activates the limbic system. Glutamate binds to inhibitory neurons, which 
inhibit limbic system activity. Chemical structures of dopamine and glutamate 
appear next to the name of each neurotransmitter. 
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(1999) suggested that the abundant release of excitatory transmitters and consequent 
overstimulation of postsynaptic neurons may be the source of the cognitive and behavioral 
disturbances connected to NMDA receptor hypofunction. This theory aligns with the dopamine 
hypothesis as the glutamatergic system is normally responsible for inhibiting dopamine activity. 
A hypoglutamateric system would disinhibit the dopaminergic system and cause 
hyperdopaminergic activity in the limbic system. 
1.3  Animal Models 
The etiology and pathophysiology of schizophrenia is poorly understood and is further 
complicated by a lack of appropriate animal models. Animal models of psychiatric disorders are 
crucial to our understanding of the neurobiological basis of schizophrenia and for the 
development of efficacious drugs (Jones et al., 2011). Animal models of human illnesses must 
meet the requirements of face, construct, and predictive validity (Figure 1-3). Face validity 
describes the degree of phenomenological similarity between the animal model and the 
symptoms of the human condition. While some symptoms, such as hyperactivity, have been 
modeled successfully, uniquely human symptoms, such as hallucinations, introduce difficulties, 
as there are currently no methods to quantify or investigate psychological processes in animals. 
Construct validity is the level of homology in pathological mechanisms. This requirement is also 
difficult to achieve for schizophrenia because the neurobiological basis of the symptoms has not 
been established. Predictive validity, the most critical feature, is the degree to which the model 
can be used to predict the efficacy of therapeutic agents in humans (Tordjman et al., 2007; 




Schizophrenia is a complex and heterogeneous disease, differing slightly for every 
individual (Wilson and Terry Jr., 2010). Thus, the likelihood of developing a single animal 
model that completely represents the range of symptoms associated with schizophrenia is 
unlikely. Focusing on specific symptoms, or specific neurobiological pathways, of the disorder 
may be the most logical approach to improving face and construct validity in animal models. 
Several animal models may then be useful for modeling various phenomenological and 
pathophysiological components of schizophrenia that could be targeted independently with 
separate molecules or multi-drug targets (Wilson and Terry Jr., 2010). 
Figure 1-3. Schematic of the three main requirements for an animal model of schizophrenia 
and the behavioral, neurochemical and structural changes expected and relevant to each 
domain. (Jones et al., 2011) 
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So far, over 20 different animal models of schizophrenia have been developed, each 
representing some aspect of the disorder. (See Jones et al. 2011 for a review on select models). 
Most models can be categorized under four different induction categories: developmental, drug-
induced, lesion, or genetic manipulation (Jones et al. 2011). Animal models that exhibit 
pathophysiological features, such as neurochemical dysfunction, are valuable to learning more 
about what pathways play a role in schizophrenia. There is growing evidence that the pathways 
related to Glutamate Carboxypeptidase II (GCPII), an enzyme responsible for glutamate activity 
and NMDAR function, are viable therapeutic targets for intervention for schizophrenia and 
related psychiatric diseases (Guilarte et al., 2008; Han et al., 2009). In the present study we used 
a genetically modified mouse that has reduced GCPII enzyme activity to replicate glutamatergic 
activity that is suspected in schizophrenia patients. 
1.4  The GCPII Mouse Model 
 The GCPII+/- mouse model is unique as it involves the glutamatergic system, a highly 
implicated pathway in schizophrenia (Han et al., 2009). While dopamine antagonists can only 
alleviate positive symptoms, treatments that reverse hypofunction of NMDA receptors can 
potentially relieve positive, negative, and cognitive symptoms. Most pharmacological treatments 
for the disease are now focusing on a glutamate-modulating class because of the limitations of 
treatments that target dopamine receptors (Nasrallah et al., 2011). 
 GCPII regulates both folate absorption and activation of NMDAR (Goff et al., 2004). In 
the jejunum GCPII hydrolyzes folylpoly-gamma-glutamate and facilitates folate absorption 
(Sacha et al., 2007). When expressed in the brain, GCPII hydrolyzes N-acetylaspartylglutamate  
(NAAG) into glutamate and N-acetylaspartate (NAA; Figure 1-4).  
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GCPII regulates NMDAR activation via glutamate and NAAG. Glutamate activates NMDAR 
while NAAG is a neuropeptide that is a NMDAR antagonist and mGluR3 agonist, which 
downregulates glutamate release (Figure 1-5).  There are discrepancies in the literature regarding 
the effect of NAAG at mGluR3 and NMDAR (Fricker et al., 2009). However, postmortem 
schizophrenia patients exhibited less GCPII activity in the prefrontal cortex, temporal cortex, and 
hippocampus compared to age matched controls, which supports the function of NAAG as stated 
above (Tsai et al., 1995). Further, these findings parallel the glutamate hypothesis and suggest 
that schizophrenia supports a hypoglutamatergic state (Coyle, 2006). 
 
Figure 1-5. Pathways of GCPII in the normal and schizophrenic brain. (Chu, 2009) 
 
Figure 1-4. Function of the GCPII enzyme 
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Our study compares heterozygous GCPII+/- (HET) mice and mutation free wild-type 
(WT) mice. HET mice were generated using the Cre-loxP system. Exons 1 and 2 of the GCPII 
gene were flanked by LoxP sites then excised by crossing with a Cre-expressing mouse. Cre is a 
recombinase protein, which mediates excision of sites located between loxP sites. In the study 
that generated this mouse model, mouse brain tissues were removed to determine GCPII protein 
expression by chemiluminesence and radioenzymatic assays, which were performed to assess 
GCPII enzyme activity. (Han et al., 2009) 
As a result of this mutation, HET mice have the GCPII gene knocked out, which causes a 
50% decrease in levels and functioning of the enzyme GCPII (Han et al., 2009). Null GCPII+/- 
mice, or mice with the GCPII gene completely knocked out, were not used as they are not viable 
(Han et al., 2009). Diminished CGPII function leads to lower levels of NAA and glutamate and 
higher levels of NAAG, thereby suppressing NMDAR function.  
 If HET mice successfully model aspects of schizophrenia, they should be behaviorally 
and neurologically different from WT mice. The study that first explored the viability of this 
model performed a battery of behavioral tests that assessed locomotor, social, and cognitive 
behaviors and found that the HET mice exhibited increased locomotor activity, reduced social 
interaction, and impaired working memory compared to WT mice (Han et al., 2009). These 
differences reflect many, but not all, of the behavioral abnormalities observed in schizophrenia 
patients. These results were expected as the GCPII+/- model only reflects the GCPII pathway of 
schizophrenia; more pathways are likely implicated. 
The goal of our developmental study was to use magnetic resonance techniques to further 
establish the face and construct validity of the GCPII+/- mouse model and to investigate sex 
differences. Male and female HET and WT mice were investigated on postnatal day (PND) 
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35/36, 49/50, and 63/64, where PND 63 corresponds to young adulthood in a mouse. If the 
GCPII+/- mouse model could replicate the pathophysiology and neurological symptoms of 
schizophrenia, then it would be expected that the longitudinal neuroanatomy and neurochemistry 
in HET mice would parallel symptoms seen in human schizophrenia.  
1.5  Magnetic Resonance Theory (Hashemi, 2004) 
The numerous definitive findings on brain abnormalities in schizophrenia have made 
brain scans increasingly important in their identification and determination of causes and 
function. Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) are non-invasive 
techniques used to investigate the longitudinal neuroanatomy and neurochemistry, respectively, 
of the GCPII+/- mouse model (Figure 1-6). This section discusses the theory behind these 
magnetic resonance techniques. 
 
 Only nuclei with an odd number of protons and/or neutrons can be detected with 
magnetic resonance. These nuclei always have at least one proton or neutron that is unpaired, 
giving the nucleus a magnetic dipole moment, or spin magnetic moment, when in a magnetic 
field (B0). In biological systems, magnetic resonance techniques take advantage of the abundance 
Figure 1-6. The brain of a mouse was imaged to produce an MR image (a). MR images 
were used to position a cuboid voxel in the hippocampus/cortex of the mouse brain from 
which an MR spectrum (b) was obtained. 
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of hydrogen, mostly present in water and fat. As this study works with mice, hydrogen, 1H, will 
be the nucleus of focus, unless otherwise noted. 
 Each nucleus has specific energy levels related to the spin quantum number S. The 
number of energy states of a nucleus is determined as follows: 
# energy states = 2S + 1 
For the hydrogen nucleus, S = ½, there are two energy states. In the absence of B0 the 
spin magnetic moments are randomly oriented so that no net magnetization is produced. When 
B0 is applied, the spin magnetic moments align parallel or antiparallel to B0, which correspond to 
low and high energy states, respectively. A slight majority of spin magnetic moments will prefer 
the lower energy state over the higher energy state causing M0, the net magnetization vector, to 




 The spin magnetic moments spin about their own axes in addition to precessing, or 
wobbling, about the axis of B0. The rate of the precession is given by the Larmor equation: 
ω0 = γB0 
where ω0 is the Larmor precession frequency of the hydrogen nuclear magnetic moment and  γ is 
gyromagnetic ratio, a constant. M0, the net magnetization of the vector sum of all the individual 
Figure 1-7. The net magnetization 
vector, M0, aligns with the magnetic 
field B0 because the majority of spin 




spins is denoted as the + z-axis in a three-dimensional coordinate system (Figure 1-8). There are 
no components along the x or y-axes because the individual spins are all out of phase. 
  
 A radio frequency (RF) pulse is a type of electromagnetic wave. When an RF pulse is 
applied along the x-axis, perpendicularly to M0, the magnetic component of the electromagnetic 
wave creates a new magnetic field, B1, in the direction of the RF pulse (Figure 1-9). If the 
frequency of the RF pulse is at the same (Larmor) frequency as the precession of the protons, 
resonance occurs. Resonance allows energy to be added to the system and enables protons in the 
low energy state to move to a high energy state. Though the strength of B1 is much weaker than 
B0, the protons respond to the new magnetic field and precess about the x-axis at a frequency of 
ω 1 = γ1B1. Consequently, M0 undergoes nutation, or a spiral motion, from the axis of B0 into the 
perpendicular x-y plane. This creates transverse magnetization. The angle to which M0 is rotated 
is determined by the gyromagnetic ratio and the strength and duration of the RF pulse. 
 
Figure 1-8. M0, the net 
magnetization (red), is along the 
z-axis. There is no x or y 
component because the spins are 
out of phase (Hashemi, 2004). 
Figure 1-9. Application of a 
radiofrequency (RF) pulse along 
the x-axis creates B1, a new 
magnetic field. This causes M0, 
the net magnetization to flip into 




When the RF pulse is turned off, the spin magnetic moments must return to their original 
orientations, or their lowest energy states, along the z-axis. They undergo two processes of 
relaxation – longitudinal and transverse. T1 is the longitudinal, or spin-lattice, relaxation time. 
T1 describes the time it takes for 63% for the spin magnetic moments to realign along the z-axis 
or for the spin magnetic moments to release the energy gained from the RF pulse. The T2 time 
constant is for transverse relaxation, or spin-spin relaxation, and describes the time it takes for 
63% of the Mxy component to decay. T2 primarily depends on the inherent dephasing caused by 
interaction between spins. T2* accounts for spin-spin interactions, but differs from T2 in that it 
considers the effects of B0 inhomogeneities. During relaxation, the precession of magnetization 
in the xy plane forms a signal. This signal is called a free induction decay (FID) and contains 
information regarding the properties of the sampled nuclei. In MRI, spatial information is 
obtained to produce a two-dimensional image. In MRS, the signal undergoes Fourier 




1.6  Magnetic Resonance Imaging (MRI) (Hashemi, 2004) 
In biological subjects, MRI uses the signals from protons in the form of water. Different 
tissues possess unique atomic compositions and can be used to provide image contrast. A pulse 
sequence is used to spatially encode these signals. In a pulse sequence, the RF pulse is applied 
multiple times, gradient coils are varied, and multiple FIDs are obtained. The information from 
these FIDs is then combined to create an image (Figure 1-10). This section gives an overview of 
these processes and how MR images are obtained.  
 
 
A pulse sequence (Figure 1-11) uses the parameters of repetition time (TR) and echo time 
(TE) to obtain T1 and T2- weighted images. 
Figure 1-10. Contiguous T2-weighted magnetic resonance images of a 





TR and TE are closely related to the previously mentioned relaxation constants T1 and T2, 
respectively. However, while T1 and T2 are inherent, TR and TE can be adjusted to provide 
optimal contrast. The time between each pair of 90o pulses is the repetition time (TR). The 
interval between the application of the RF pulse and the measurement of a signal is the echo time 
(TE). A short TR and TE are optimal for T1-weighted contrast where fat is bright and water is 
dark. Accordingly, a long TR and TE produces T2-weighted contrast where water is bright and 
fat is dark. These differences are based on the T1 and T2 relaxation times of protons in different 
environments. Cerebrospinal fluid (CSF) is mostly comprised of water and has a long T2 
compared to white matter, which contains fat. Thus given time after an RF pulse, the magnetic 
moments in CSF will have dephased less than the protons in white matter and will have greater 
signal intensity (Figure 1-12). 
Figure 1-11. Spin-echo pulse sequence diagram. The 90o pulse flips the spin 
magnetic moments into the x-y plane. The 180o pulse is then applied to flip the 
spin magnetic moments 180o in the x-y plane. Thus, this second pulse causes a 





In order to create spatially organized two-dimensional MR images, gradient coils are 
used. A gradient coil is an electrical device composed of loops of wire that perturb B0 to create a 
magnetic field gradient. The three gradients, slice-select (Gz), phase-encoding (Gy), and 
frequency-encoding (Gx), each serve a unique function. During the pulse sequence, each gradient 
is applied at a specific point in the sequence (Figure 1-11). Gz is applied during pulse application 
and varies B0 linearly along the z-axis. Gz enables a slice to be selected based on a frequency 
range in the RF pulse that corresponds to the slice location and thickness. In order to differentiate 
points within the slice, Gx is applied between pulses and during readout. Gx distinguishes proton 
frequencies along the x-axis. Gy is then applied between pulses or before readout in the y-axis 
and distinguishes protons by their phase. These latter two gradients can differentiate pixel-
specific properties in the x-y plane. Each time Gy with a different value is applied, one line is 
added to k-space, a digitized space for data from each slice. The data in k-space then undergo 
Fourier Transformation and are converted from the time domain to the frequency domain to 
produce an MR image. 
MRI is useful for structural studies because the technique can non-invasively visualize 
and create contrast among anatomical structures based on the unique characteristics of protons in 
tissue. This is relevant to schizophrenia as schizophrenia patients exhibit structural brain 
abnormalities. Human studies on schizophrenia have found an enlargement of ventricles, 
Figure 1-12. T1 recovery (left) 
and T2 decay (right) curves of 
white matter (WM), grey matter 
(GM), and cerebrospinalfluid 
(CSF) (Hashemi, 2004). 
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asymmetrical lateral ventricles, asymmetric hippocampi, and a reduced hippocampus (Shenton et 
al. 2001, Tsai, 2002). Previous work with the GCPII+/- mouse model found that the hippocampus 
was reduced and asymmetric, lateral ventricles were asymmetric, and third ventricle was 
enlarged in GCPII+/- compared to WT (Mu, 2011). Through this study we hope to replicate these 
findings with statistical significance and validate the GCPII+/- mouse model. 
1.7  Magnetic Resonance Spectroscopy (Hornak, 2011) 
Following an MRI experiment, the MR images are used to specify a voxel, or volume of 
tissue in the brain, to perform in-vivo 1H-MR spectroscopy (MRS), which uses the signal from 
hydrogen protons to non-invasively investigate the concentration of brain metabolites.  
Brain metabolites are differentiated in MRS by their chemical properties. The electrons 
surrounding a nucleus can create a small magnetic field that opposes or enhances B0. This new 
magnetic field causes the effective magnetic field, Beff, at the nucleus to be greater or less than 
B0: 
Beff = B0 (1- σ) 
The value of σ depends on the electron density of protons, which are unique for each molecule 
and depends on the type of nuclei and bonds. When a signal is collected and Fourier 
Transformed, a spectrum is created in which protons in molecules can be identified as unique 
peaks along the x-axis labeled in parts per million (ppm; Figure 1-13). A proton with an electron 
density that enhances B0 will appear downfield in a spectrum. Conversely, a proton with an 
electron density that opposes B0 will appear upfield. Each peak can represent one or more 
molecule(s) and the area under the peak is proportional to the concentration of the molecule(s). 
The location of each molecule on the x-axis is determined by its chemical shift, δ, and compared 
 18 
relative to a reference frequency. In this study, we use the (NAA+NAAG) peak as a reference as 
it has a unique shape and is easy to distinguish in spectra of the mouse brain. 
 
In order to perform MRS, the magnetic field must be made homogenous. This is achieved 
by shimming, which is an automated or manual process that homogenizes the magnetic field by 
adjusting shim coils (Gujar et al., 2005). In this study, shimming is accomplished with a 
FASTMAP pulse sequence that automatically adjusts first and second order shims. 
MRS investigates neurometabolites, whose concentrations are much smaller than that of 
water. Thus it is necessary to suppress the water signal so that it does not overwhelm the 
metabolite signals (Gujar et al., 2005). This is achieved by exciting the water protons with an RF 
pulse, then dephasing the water protons with a crusher, or spoiler, gradient. This results in a 
smaller water peak in the spectrum. Outer volume suppression is also necessary to suppress 
signals surrounding the voxel. 
Figure 1-13. 1H-MR spectrum of a mouse brain. Metabolites are 
labeled above their respective peaks. 
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In this study, a Point-RESolved Spectroscopy (PRESS) pulse sequence was used for 
volume selection. In this pulse sequence, three separate pulses are applied, in the x-, y-, and z- 
axes, and with 90o, 180o, and 90o flip angles, respectively. The intersection of these pulses results 
in a volume of interest, or voxel, from which a spectrum is obtained.  
Metabolites were analyzed from a cuboid voxel positioned primarily in the hippocampus 
and cortex. This region was selected because the hippocampus is linked to the limbic system and 
is known to function differently in schizophrenia patients (Harrison, 2003; Hecker 2001; Shenton 
et al., 2001) With our current spectroscopy parameters, the metabolites that can be resolved are 
Choline (Cho), Creatine (Cr), Taurine (Tau),N-acetylaspartate + N-acetylaspartylglutamate 
(NAA + NAAG), and Glutamate + Glutamine (Glu and Gln; Glx) (Table 1-1). 
 20 





































































1.8 Metabolites of Interest 
Choline 
 The Cho peak in MR spectra is a combination of several choline-containing compounds 
including glycerophosphocholine, phosphatidylcholine, and phosphocholine (Govindaraju et al., 
2000). Cho is a precursor for cytidine diphosphate choline, a mononucleotide involved in the 
synthesis of phospholipid structural components of cell membranes. Changes in Cho levels are 
indicative of changes in neuronal membrane composition (Bracken et al., 2011, Govindaraju, 
2000). Increased Cho is thought to signal either an increase in the amount of cell membrane per 
unit volume or an increase in the release of Cho during the breakdown of myelin as in the case in 
neurodegenerative disorders (Bracken et al., 2011). Reductions in Cho levels have been found in 
the left hippocampus of schizophrenia patients compared to controls (Maier et al., 1995).  
Creatine 
 Cr, including phosphocreatine (PCr), is a non-essential nutrient and a marker for brain 
energy metabolism. It plays a role in energy metabolism, especially in neurons where energy 
requirements are high and fluctuate (Andres et al., 2008). In MRS studies, the magnitude of Cr 
has largely been used as an internal reference (Ongur et al., 2009). In this study, metabolite 
levels are reported as ratios in comparison to Cr. There is some concern regarding this practice 
because patients with schizophrenia have lower Cr levels than controls. However, this should not 
be a problem if Cr levels are shown to be normal in the study population (Ongur et al., 2008). In 
this study, Cr levels have been used as an internal reference based on previous work that 
determined sufficient controls (Mu, 2011). 
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Taurine 
 Tau is a semi-essential amino acid. In mammals, Tau is the most abundant amino acid in 
the heart, retina, skeletal muscle, brain, and leukocytes (Schuller-Levis and Park, 2003). Tau is 
thought to protect cell membranes from toxins and act as a neuroprotectant by increasing neural 
acetylcholine levels, helping neuronal growth and survival (Schuller-Levis and Park, 2003). Tau 
uptake and release may also represent a form of communication between neurons and glial cell 
(Sturman, 1988). Elevated levels of Tau were found in the prefrontal cortex of schizophrenia 
patients, suggesting a response to increased oxidative stress due to metabolic abnormalities in 
schizophrenia (Shirayama et al., 2009). Previous work with the GCPII+/- mouse model also found 
increased Tau levels in GCPII+/- mice compared to WT (Chen, 2010; Mu, 2011).  
N-acetylaspartate and N-acetylaspartylglutamate 
 NAA is a metabolite of NAAG.  NAA is synthesized by neuronal mitochondria and is 
abundantly located in neurons throughout the brain. NAA is known to be a marker of neuronal 
integrity as levels of NAA are altered in a wide range of disorders. However, the biological role 
of NAA in the brain is unclear (Coyle, 2006). Changes in NAA levels may be indicative of 
spine/synapse number, neuron size, neuron density, or some combination of these (Bracken et 
al., 2011). 
 In schizophrenia patients, in-vivo levels of NAA have been found to be reduced in several 
regions of the brain including the hippocampus (Bertolino et al., 1997; Deicken et al., 1998; 
Miyaoka et al., 2004; Nasrallah et al., 1994; Steen et al., 2005) and cortical gray matter (Bustillo 
et al., 2011; Tayoshi et al., 2011). This is consistent with a reduction in GCPII activity and with 
the process of early dendritic retraction. Correlation was also discovered between NAA levels 
and social functioning in schizophrenia patients suggesting that NAA may also be an indicator of 
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disease severity (Sigmundsson et al., 2003).  
 NAAG is a neuroactive peptide and is localized to subpopulations of glutamatergic, 
cholinergic, GABAergic, and noradrenergic neuronal systems (Coyle, 1997). As previously 
mentioned, NAAG is an agonist at mGluR3 receptors and an antagonist at NMDA receptors. 
NAAG is hydrolyzed to N-acetylaspartate and glutamate by GCPII, which is expressed on the 
extracellular surface of astrocytes. The levels of NAAG and the activity of GCPII are altered in a 
regionally specific fashion in several neuropsychiatric disorders (Coyle, 1997). Postmortem 
studies of NAAG levels in schizophrenia patients have found increases of NAAG in the 
hippocampus (Tsai et al., 1995). 
 Based on the glutamate hypothesis, we expect to find reduced levels of NAA and 
increased levels of NAAG in GCPII +/- mice compared to WT mice. NAA and NAAG contribute 
to the same chemical peak in the 1H-MRS spectrum and are not distinguishable. If the only factor 
were the conversion between NAA and NAAG, we would expect this peak, referred to as 
(NAA+NAAG), to remain the same between GCPII+/- and WT mice. However, other problems 
that account for the viability of cells may result in reductions of NAA (Steen, 2005). 
Accordingly we expect the (NAA+NAAG) peak to be reduced in GCPII+/- compared to WT 
mice. 
Glutamate and Glutamine 
 Glu and Gln are both non-essential amino acids. Glu is the primary excitatory 
neurotransmitter in the brain, while Gln is its precursor and byproduct. In Glu-Gln cycle, Glu and 
Gln are interconverted into each other (Figure 1-14). 
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In glial cells, or non-neuronal cells such as astrocytes, Glu is converted into Gln while in 
the central nervous system Gln is either used for other neuronal processes or converted back to 
Glu and stored for future use (Rothman et al., 1999). Glu can also be produced de novo from 
tricyclic intermediates in the presynaptic neuron The rate that Glu is released and processes that 
follow are controlled by neuronal and metabolic activity through stimulation of extrasynaptic 
glutamate receptors, such as mGlur3 (Yuksel and Ongur, 2005). Glu and Gln appear at similar 
chemical shifts and are indistinguishable using in-vivo MRS. Thus these metabolites are 
quantified together as Glx. 
 
  
Figure 1-14. The glutamate–glutamine (Glu-Gln) cycle. Glu is released from the presynaptic 
neuron into the synaptic cleft where it acts on postsynaptic receptors, such as NMDA and 
other Glu receptors. Glu is further removed from the synaptic cleft by glutamate transporters 
(EEAT1 and EAAT2) which are mainly located on astrocytes. Within the astrocyte, ammonia 
and Glu combine to form Gln via glutamine syntehtase (GS), an astrocyte-specific enzyme. In 
order to replenish stores of Glu, Gln is released from astrocytes and enters the presynaptic 
neuron. Once inside the neuron, neuron phosphate-activated glutaminase (GLNase) splits Gln 




The glutamate hypothesis predicts that schizophrenia will function in a 
hypoglutamatergic state. Accordingly, decreased levels of Glu have been found in schizophrenia 
patients (Tsai et al., 1995; Tayoshi et al. 2008; Guilarte et al., 2008). In schizophrenia, Glx levels 
were found to be a marker of cognitive function where levels of Glx were positively correlated 
with overall cognitive performance (Bustillo et al., 2011). These findings confirm a change in the 
glutamatergic system and suggest an involvement in the pathophysiology of schizophrenia. 
However, it must be noted that an increase, lack of change, and decrease of Glx or Glx/Cr in 
schizophrenia patients have also been found in various studies (Tayoshi et al., 2009). This is 
likely due to regional differences or time of sampling as Glu concentrations are thought to be 
higher in the acute stage, but lower in chronic stage (Tayoshi et al., 2009). Our study focuses on 
the hippocampus with the stage, acute or chronic, unknown. As GCPII activity is prominent in 
the hippocampus related to levels of Glu, we expect our findings to parallel MRS studies of the 
hippocampus, which reported decreased levels of Glu (Tayoshi et al., 2009; Tsai et al., 1995).  
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2 Materials and Methods 
 
2.1  Subjects and Subject Maintenance 
All experiments were conducted on GCPII+/- (HET) mice or C57BL/6  (WT) mice, which 
descended from the founding colony at McLean hospital (Belmont, MA). HET mice contain a 
knockout of the GCPII gene and exhibit reduced GCPII enzyme function (Han et al., 2009), 
while WT mice have no genetic modification and serve as controls. HET mice were bred on a 
WT mice background for over 9 generations with procedures approved by the Wellesley College 
Institutional Animal Care and Use Committee and conform to the standards set forth in the 
National Institute of Health Guide for the Care and Use of Laboratory Animals. HET dams were 
mated with WT male mice and the day after birth was considered postnatal day (PND) 1.  
WT and HET mice were weaned on PND 21 and separated by sex into standard sized 
mouse cages that contained at least 2 mice and held a maximum of 4 mice. There were four types 
of mice used: HET males (n = 4), WT males (n = 6), HET females (n = 7), and WT females (n = 
7), and. Mice were exposed to a 12:12 light-dark cycle and temperatures of 21 ± 1 oC with food 
and water available ad libitum. Markings were periodically drawn on mice tails for 
identification. For genotyping, mice ears were clipped and ear samples were sent to Mouse 





2.2  In vivo Magnetic Resonance Imaging and Spectroscopy 
Brain MR images of each mouse were obtained on PND 35/36, 49/50, 63/64 on a 9.4 T 
Bruker Avance DRX 400 MHz vertical bore NMR spectrometer equipped with a MicroMouse 
2.5 imaging accessory (Bruker Biospin, Billerica, MA). Bruker ParaVision 4.0 and Bruker 
Topspin 1.5 software (Ettlingen, Germany) were used to acquire images and analyze spectra, 
respectively, on a Linux system.  After imaging, all data were analyzed using a genotype-blind 
protocol with Analyze 10.0 image analysis software (Mayo Clinic, Rochester, MN). 
2.3  Animal Preparation 
Mice were anesthetized with 1-1.5% isofluorane in oxygen, at a flow rate of 0.2 L/min in 
a plexiglass chamber (Braintree Scientific, Inc., Braintree, MA). Once a mouse was anesthetized, 
approximately 10 minutes after exposure to isoflurane/O2, the isoflurane/O2 flow was directed 
into the nose cone of a mouse bed (Wellesley College, Wellesley, MA), which has an opening 
for the exhaust tube and is located inside the micro-imaging probe (Figure 2-1). The exhaust tube 
was connected to a F/AIR Scavenger activated charcoal filter (Paragonmed, Coral Springs, FL) 
to prevent airborne contaminants from entering the environment. The mouse was then transferred 
to the mouse bed where it was positioned using a bite bar and secured using 3M MicroporeTM 
tape (St. Paul, MN). Once taped into the mouse bed, the breath rate of the mouse was monitored 
with a respiration sensor pad (SA Instrument, Inc., Stony Brook, NY) configured with BioTrig 
Builder 1.01 Software (Bruker Biospin, Billerica, MA) on a PC system. The breathing rate was 
maintained between 30 and 100 breaths per minute by adjusting the isoflurane level with a VIP 













Once the mouse was secured in the mouse bed and inserted into the probe, the probe was 
positioned in the spectrometer to center the brain in the magnet and gradient coils. Throughout 
the experiment, a water circulation unit was used to maintain the temperature of the coils 
surrounding the mouse at 32 oC to help the mouse maintain a body temperature. 
2.4  Magnetic Resonance Imaging 
The probe was tuned and matched before imaging or acquiring spectra. A RARE_tripilot 
sequence was used to visualize the mouse’s position in three orthogonal slices (TE = 12.500 ms, 
TR = 2000.000 ms, rare factor = 8, matrix size = 128x128, number of averages = 1). The 
Figure 2-1. Mousebed (A; top view). Arrows, as labelled, indicate location of bite bar, 
respiration sensorpad, and air inputs. Mousebed with mouse positioned inside (B; side 
view). Mousebed with mouse secured (C; topview). 
 
 29 
RARE_tripilot images were then used to position the field-of-view (FOV) on the entire mouse 
brain (Figure 2-2). If the brain was not centered in the gradients, the mouse was removed, 
repositioned, and the RARE_tipilot scan was repeated. Next, 24 contiguous coronal MR images 
of 0.7 mm thick slices were acquired with a RARE_8_bas T2 weighted pulse sequence (TE = 15 
ms, TR = 3109 ms, Tx0 ~ 15 dB, Tx1 ~ 5.2 dB, FOV = 2.6 cm2, averages =16). A pre-scan 
macro was used to automatically adjust the attenuators, receiver gain, and shim settings. 
 
2.5  Magnetic Resonance Spectroscopy 
Following the imaging portion of the experiment, with the mouse still in the magnet, a 
spectrum of the hippocampus region was obtained. With the Geometry Editor tool, a 4x4x4 mm3 
(64 µL) voxel was positioned to include the hippocampus using the RARE_8_bas images as a 
reference. A fastmap_4mm scan automatically adjusted first and second order shims over the 
cubic region. The voxel was reduced to a 4x2x3 mm3 (24 µL) cube focused on the hippocampus 
Figure 2-2. Selection of 24 continguous slices on a sagittal 
RARE_tripilot image of a mouse brain.  
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(Figure 2-3). The PRESS_waterline pulse sequence was used to obtain a water peak (TE = 20 
ms, TR = 2000 ms, averages = 8). This sequence included Outer Volume Suppression (OVS) but 
not water suppression. The spectrum obtained from PRESS_waterline was analyzed with Bruker 
TopSpin 1.5 software to determine the linewidth of the water peak. If the width was larger than 
25 Hz, the spectrum could not be obtained and fastmap_4mm was repeated to further 
homogenize the magnetic field. With a satisfactory water peak, the final metabolite spectrum 
was obtained using the Press-1H pulse sequence with VAPOR water suppression and outer 
volume suppression (OVS) (TE= 20 ms, TR = 2000 ms, Tx0~ 150, Tx1~ 9.4, averages = 800).  
 
After the spectrum was acquired, the mouse was removed from the probe and was 
monitored on a heating pad until it recovered full consciousness.  
2.6  Data Analysis 
MRI Data Analysis 
After imaging, all data were analyzed using a genotype-blind protocol with Analyze 10.0 
image analysis software (Mayo Clinic, Rochester, MN). Whole brain, cerebellum, fourth 
ventricle, third ventricle, left and right hippocampus, and left and right lateral ventricles were 
traced as separate objects with the Region of Interest Tool and Wacom Cintiq 12WX tablet 
Figure 2-3. A 4x2x3 mm3 cuboid voxel positioned on the hippocampus in 5 slices, which were 
contiguous and each had a thickness of .7 mm.  
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display (Wacom Co., Ltd., Tokyo, Japan). A stereotaxic atlas was used as a reference to 
determine regional borders of structures and structural markers (Paxinos and Franklin, 2004). 
Three laboratory members, including the author, traced the brains in order to minimize the total 
amount of tracing for each person and maximize tracing consistency for each brain structure. 
Each person traced specific structures in every brain; one traced the whole brain, another the 
cerebellum, and the final traced all other structures (See Appendix-A for tracing guide). The final 
traces were then combined and the Sample Images tool on Analyze 10.0 was used to determine 
the volume of each structure. The combined area of each traced region was multiplied by the 
summed thickness of the slices for the relevant brain region. 
MRS Data Analysis 
The spectral peaks were analyzed with Bruker TopSpin 1.5 to determine relative 
metabolite concentrations. Line broadening, or exponential multiplication, of 10 Hz was applied 
to the FID to improve the signal to noise ratio of the spectrum. The reduction of noise made the 
spectrum lines smoother and easier to read. The spectra were then phased and calibrated, where 
the distinguishable (NAA+NAAG) peak was set to 2.01 ppm. The troughs between each pair of 
peaks were marked as baseline points. The deconvolution tool was then used to fit Gaussian 
curves under each peak and provide the calculated area under the Gaussian peaks. Each peak of 
the spectrum represents the unique properties of equivalent protons in the neurometabolites. The 
Gaussian peak area could then be used to represent the levels of a specific neurometabolite. The 
metabolites Cr, Tau, Cho, Glx, and (NAA+NAAG) were resolved and compared to Cr (3.0 ppm), 




All data were analyzed by genotype and PND with males and females grouped 
separately.  Independent unpaired two-tailed t-tests assuming unequal variances were used to 
detect differences between genotypes at a single time point. Paired t-tests were used to detect 
developmental differences within a genotype between two time points. Bar graphs were created 
to represent mean volume or ratio of brain structures or metabolites with error bars representing 
standard deviation. All analyses were performed using Microsoft Excel where a p < 0.05 was 
considered significant. Q-tests were performed to detect outliers, but outliers were not removed 
given the small sample size of data.  
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3 Results and Discussion 
3.1  Magnetic Resonance Imaging 
MRI data were collected from the same HET males (n = 4), WT males (n = 6), HET 
females (n = 7), and WT females (n = 7) on PND 35/36, 49/50, and 63/64. The effect of sex 
differences on MRI data were first examined in HET and WT mice. Because sex differences 
were found between male and female mice, all data from males and females were analyzed 
separately. The volume or volume ratio of each structure was averaged at each time point for all 
mice in each of the four groups. Brain structures volumes were normalized to the whole brain 
volume (WBV) to account for size differences among mice. WBV, cerebellum to WBV ratio 
(C/WB), fourth ventricle to WBV ratio (4V/WB), third ventricle to WBV ratio (3V/WB), lateral 
ventricle to WBV ratio (LV/WB), left to right lateral ventricle volume ratio (Left/Right LV), 
hippocampus to WBV ratio (HP/WB), and left to right hippocampus volume ratio (Left/Right 
HP) were examined for all mice. The individual volume trends of four mice, one mouse of each 




Phenotypic differences between male and female mice (sexual dimorphisms) were 
examined in HET and WT mouse brain structures. Male HET mice had significantly larger 
cerebellum to WBV ratios than females on PND 63 (t(9) = 1.833, p < .01; Figure 3-1B). At all 
time points, male HET mice exhibited a greater left to right hippocampus ratio than female HET 
mice and was significantly different on PND 49 (t(9) = 1.833, p = 0.01; Figure 3-1H). Female 
WT mice had larger cerebellum to WBV ratios than male WT mice at all time points and trended 
towards significance on PND 63 (t(11) = 1.796, p = 0.050; Figure 3-2B). At all time points, male 
WT mice had larger whole brain volumes compared to female WT mice and male HET mice had 
smaller whole brain volumes compared to female HET mice (Figure 3-1A and 3-2A). No 
significant volume differences were found between male and female WT mice at any time point. 






Figure 3-1. Mean brain structure volume or ratio ± SD between GCPII+/- heterozygous (HET) males (M) 
and females (F) from postnatal day 35 to 63. Regions analyzed were A. Whole brain (WB), B. Cerebellum 
(C) to WB ratio, C. Fourth ventricle (4V) to WB ratio, D. Third ventricle (3V) to WB ratio, E. Lateral 
ventricle (LV) to WB ratio, F. Hippocampus (HP) to WB ratio, G. Left LV to right LV ratio, H. Left HP to 
right HP ratio. Key on the bottom left indicates sex and genotype. Data from the same mice were collected 
over time. Regions were manually traced and volume was calculated using the Region of Interest tool on 
Analyze 10.0. * indicates a significant difference (p < 0.05) between genotypes at a single time point as 




Figure 3-2. Mean brain structure volume or ratio ± SD between wild-type (WT) males (M) and 
females (F) from postnatal day 35 to 63. Regions analyzed were A. Whole brain (WB), B. Cerebellum 
(C) to WB ratio, C. Fourth ventricle (4V) to WB ratio, D. Third ventricle (3V) to WB ratio, E. Lateral 
ventricle (LV) to WB ratio, F. Hippocampus (HP) to WB ratio, G. Left LV to right LV ratio, H. Left 
HP to right HP ratio. Key on the bottom left indicates sex and genotype. Data from the same mice 
were collected over time. Regions were manually traced and volume was calculated using the Region 
of Interest tool on Analyze 10.0. † indicates a trend towards a significant difference between 






Sexually dimorphic characteristics have been found in both human and mouse brains, but 
the etiology of these differences is not well understood (Goldstein et al., 2001; Spring et al., 
2007). Our finding that the male WT whole brain is larger than the female WT whole brain 
agrees with a 3D MRI study that examined the same WT (C57BL/6) mice (Spring et al., 2007). 
Volume studies on humans report similar results (Chance et al., 2003; Goldstein et al., 2001). 
Differences in whole brain size may stem from the release of different sex hormones (Cooke et 
al., 1999; Goldstein et al., 2001). Cooke et al. (1999) found that adult hormone manipulation can 
completely reverse sexual dimorphism in the postdorsal component of the medial amygdala of 
rats. However, hormone manipulation could not reverse all sexually dimorphic neural volumes. 
This suggests that non-biological factors, such as behavior and environment, may also play a role 
in the development of sexually dimorphic characteristics. 
Brain metabolic (Tayoshi et al., 2009), morphologic (Springer et al., 2007; Takayanagi et 
al., 2009), behavioral (Seeman et al., 1997), and hormonal (Seeman et al., 1997) sex differences 
have been observed in schizophrenia patients. Males experience an earlier onset and a more 
severe form of schizophrenia than females, as males experience more negative symptoms and 
exhibit greater brain abnormalities (Seeman et al., 1997). These findings may relate to 
morphological changes, which are more prominent in male subjects as compared to females 
(Tayoshi et al.; 2009). Reduced WBV is a characteristic of male and female schizophrenia 
patients (Nakamura et al., 2004; Steen et al., 2006). While we do not see significantly reduced 
WBVs in our mouse model, we found that male HET mice had smaller WBVs than female HET 
mice. This suggests that male HET mice exhibit greater morphological changes than female HET 
mice, as male WT WBVs are normally greater than WT female volumes. Hippocampus 
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asymmetry is also a characteristic of schizophrenia patients (Harrison, 2003; Heckers, 2001; 
Petty, 1999). Our finding that male HET mice exhibit greater asymmetry, or a larger left to right 
hippocampus ratio than female HET mice, further confirms that HET males are more affected 
than females. Cerebellum to WBV sex differences were apparent in WT mice and significant in 
HET mice. However, each genotype exhibited opposite trends – female WT mice had larger 
C/WB ratios than male WT mice and vise versa for HET mice. These differences are, once 
again, likely related to male HET mice exhibiting greater morphological changes than female 
HET mice as an enlarged cerebellum is a characteristic of schizophrenia patients (Levitt et al., 
1999). Other reasons for observed differences in brain structures are discussed later in each 
region’s respective section (See Cerebellum finding, p. 45). 
Collectively, these findings suggest volumetric differences between male and female 
brains in both WT and GCPII+/- mice. In order to control for sex differences, all volume analyses 






Whole Brain Volume Results 
WBV was significantly greater for HET female mice than for WT female mice on PND 
63 (t(12) = 1.782, p = 0.03; Figure 3-3A). WBV significantly increased from PND 35 to 63 for 
female WT (t(12) = 1.782, p = 0.02), female HET (t(12) = 1.782, p < .01) and male HET mice 
(t(6) = 1.943, p = 0.04; Figure 3-3). WBV significantly increased from PND 35 to 49 for female 
HET (t(12) = 1.782, p < .01) and female WT mice (t(12) = 1.782, p = 0.03; Figure 3-3A). Only 
female HET mice showed a significant increase in WBV from PND 49 to 63 (t(12) = 1.782, p < 
0.01; Figure 3-3A). At all time points, male WT mice had larger WBVs than male HET mice 
(Figure 3-3B).  
Table 3-1. MRI brain volume data for male WT, male HET, female WT, and female HET mice. A. * 
indicates a significant difference between WT and HET mice at that time point (p < 0.05). † indicates 
a trend towards significance between WT and HET mice (0.05 < p < 0.07). B. * indicates a significant 
developmental difference between indicated time points within a genotype and sex (p < 0.05). † 






Whole Brain Volume Development 
Structural studies have found reduced WBVs in schizophrenia patients compared to 
controls (Nakamura et al., 2004; Steen et al., 2006). Our result that male HET WBVs appear 
smaller than male WT WBVs at all time points agrees with these findings. A meta-analysis of in 
vivo MRI studies on the brain volume of schizophrenia patients suggests that the whole brain of 
schizophrenia patients may not exhibit progressive deficits (Steen et al., 2006). In other words, 
the whole brain in schizophrenia patients is growing at the same rate as a healthy person. Steen et 
al. (2006) hypothesized that abnormalities in brain development, which begin after birth or after 
the onset of symptoms, are what cause the brain to be smaller than healthy controls. If abnormal 
brain development begins later for the GCPII+/- mouse model, it is possible that male and female 
HET mice would exhibit significantly smaller WBVs compared to, respectively, male and female 
WT mice at later time points. WBV growth from PND 35 to 63 for male and female HET mice 
Figure 3-3. Mean whole brain volume ± SD of A. wild-type (WT) and GCPII+/- heterozygous 
(HET) females and B. WT and HET males from postnatal day 35 to 63. Keys above graphs 
indicate sex and genotype. Data from the same mice were collected over time. Regions were 
manually traced and volume was calculated using the Region of Interest tool on Analyze 10.0. * 
indicates a significant difference (p < 0.05) between genotypes at a single time point as 
determined with unpaired two-tailed student t-tests assuming unequal variances or a significant 
developmental difference within a genotype and between two time points as determined with 





was expected, as WBV of both healthy and schizophrenic individuals is known to increase over 
time. WBV growth from PND 35 to 63 for male WT mice would likely reach significance with a 
larger sample size as this pattern was observed in all other mice.  
 
Cerebellum to Whole Brain Volume Ratio Results 
female HET mice had significantly lower cerebellum to WBV ratios on PND 63 
compared to female WT mice (t(12) = 1.782, p = 0.02; Figure 3-4A), whereas male HET mice 
had significantly higher cerebellum to WBV ratios on PND 63 compared to male WT mice (t(8) 
= 1.860, p = 0.04; Figure 3-4B). At all time points, male HET mice had higher cerebellum to 
WBV ratios than male WT mice. Female mice exhibited the opposite pattern; female HET mice 
had lower cerebellum to WBV ratios compared to female WT mice. 
 
Figure 3-4. Mean cerebellum to whole brain volume ratio ± SD of A. wild-type (WT) and GCPII+/- 
heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Keys above 
graphs indicate sex and genotype. Data from the same mice were collected over time. Regions were 
manually traced and volume was calculated using the Region of Interest tool on Analyze 10.0. * 
indicates a significant difference (p < 0.05) between genotypes at a single time point as determined 
with unpaired two-tailed student t-tests assuming unequal variances.  
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Cerebellum Findings on PND 63 May be Linked to Sexual Dimorphism 
Few studies have examined the role of the cerebellum in schizophrenia patients, as 
schizophrenia is known to primarily affect structures associated with the cerebrum and limbic 
system. While the cerebellum is primarily associated with motor function, there is evidence that 
the cerebellum may play a role in higher cognitive function (Andreason and Pierson, 2008; 
Shenton et al., 2001; Yeganeh-Doost et al., 2011). This was partially confirmed by Levitt et al. 
(1999) in a study that investigated the vermis, a structure in the cerebellum, and found greater 
vermis white matter volume is correlated to positive symptoms and thought disorder in 
schizophrenia. Further, they found that the vermis is enlarged in schizophrenia patients compared 
to controls (Levitt et al., 1999). Our findings that male HET mice had significantly larger 
cerebellum to WBV ratios on PND 63 and non-significantly larger ratios on PND 35 and 49 
agree with this study. Conversely, other studies found that cerebellum volume is reduced (Martin 
and Albers, 1995) or remains unchanged (Steen et al., 2006) in schizophrenia patients compared 
to controls. The former study agrees with our finding that WT female mice have larger 
cerebellums than HET female mice on PND 63. While previous work in our lab found no 
difference in cerebellum to WBV ratio between HET and WT mice, male and female data were 
combined in the analysis (Mu, 2011). Our data suggest sexual dimorphism could account for the 
observed differences, but a larger sample size or data from later time points are needed to make 
our results more conclusive. If it was determined that female and male HET mice show 
significantly smaller and larger cerebellum to WBV ratios compared to WT mice, respectively, 




Fourth Ventricle to Whole Brain Volume Ratio Results 
The fourth ventricle to WBV ratios of male HET mice were significantly higher than 
those of male WT mice on PND 49 (t(8) = 1.860, p = 0.01; Figure 3-5B). There was a trend 
toward significance where fourth ventricle to WBV ratio increased from PND 49 to 63 for male 
HET mice (t(6) = 1.943, p = 0.048; Figure 3-5B). There were no fourth ventricle to WBV ratio 
trends observed for female HET and WT at any time point or between time points for each 
genotype (Figure 3-5A). 
 
Fourth Ventricle Enlargement in Male HET Mice 
Increased ventricular volume is a common characteristic of schizophrenia (Shenton et al., 
2001). However, there is dispute regarding fourth ventricle character in schizophrenia. Out of the 
five in vivo MRI studies reviewed in a meta-analysis, four found no difference in fourth ventricle 
volume between schizophrenia patients and controls (Shenton et al., 2001). The one study with 
Figure 3-5. Mean fourth ventricle to whole brain volume ratio ± SD of A. wild-type (WT) and 
GCPII+/- heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Keys 
above graphs indicate sex and genotype. Data from the same mice were collected over time. Regions 
were manually traced and volume was calculated using the Region of Interest tool on Analyze 10.0. * 
indicates a significant difference (p < 0.05) between genotypes at a single time point as determined 
with unpaired two-tailed student t-tests assuming unequal variances. † indicates a trend towards a 




positive findings, by Keshavan et al. (1998), found that the fourth ventricle was enlarged in the 
superior temporal gyrus of schizophrenia patients compared to controls. Our findings that male 
HET mice exhibit significantly larger fourth ventricle to whole brain volume ratios than male 
WT mice support these results. However, our findings were only significant at the one time 
point, PND 49. As we only found differences between genotypes in males, it is possible that 
there is an effect of sexual dimorphism on fourth ventricle development. A greater sample size is 
needed to see if these differences also occur on PND 35 and 63 in male mice or at any time point 
in female mice.  
We found that male WT mice exhibited an increase in fourth ventricle to WBV ratio from 
PND 49 to 63 and trended towards significance. However, it is difficult to analyze or compare 
our findings, as there were no studies that related developmental trends of the fourth ventricle in 
humans to mice. It would be interesting to see if a larger sample size would reveal this pattern in 
other groups of mice, as it would suggest that an increase in fourth ventricle to WBV ratio from 
PND 49 to PND 63 is a part of normal brain growth. 
 
Third Ventricle to Whole Brain Volume Ratio Results 
Female HET mice had significantly higher third ventricle to WBV ratios compared to 
female WT mice on PND 35 (t(12) = 1.782, p = 0.0332; Figure 3-6A). There were no third 
ventricle to WBV ratio trends observed for male HET and WT at any time point or between time 
points for each genotype (Figure 3-6B) 
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Third Ventricle Enlargement in Female HET Mice 
Structural studies have found enlargement of the third ventricle in schizophrenia patients 
compared to controls (Nakamura et al., 2004; Shenton et al., 2001; Tsai et al., 2002). Previous 
work in our lab found the third ventricle to WBV ratio to be increased in male and female HET 
mice compared to controls on PND 77. Our findings that female HET mice exhibit significantly 
larger third ventricles than female WT mice on PND 35 agree with these studies. Shenton et al. 
(2001) hypothesizes that increased fluid in the third ventricle observed in schizophrenia patients 
may be related to reduced volume of the thalamus– a limbic system structure adjacent to the 
hypothalamus. Thus, an enlarged third ventricle may be linked to abnormal thalamus 
development.  Additional differences between genotypes would likely reach significance on 
PND 49 as differences are apparent, but not yet significant.  
 
Figure 3-6. Mean third ventricle to whole brain volume ratio ± SD of A. wild-type (WT) and GCPII+/- 
heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Keys above 
graphs indicate sex and genotype. Data from the same mice were collected over time. Regions were 
manually traced and volume was calculated using the Region of Interest tool on Analyze 10.0. * 
indicates a significant difference (p < 0.05) between genotypes at a single time point as determined 
with unpaired two-tailed student t-tests assuming unequal variances. 
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Lateral Ventricle to Whole Brain Volume Ratio Results 
Female HET mice exhibited significantly higher lateral ventricle to WBV ratios 
compared to female WT mice on PND 35 (t(12) = 1.782, p = 0.01; Figure 3-9A). Female WT 
lateral ventricle to WBV ratio showed a significant increase from PND 35 to 63 (t(12) = 1.782, p 
= 0.02; Figure 3-9A). Female WT lateral ventricle to WBV ratios on PND 49 were higher than 
on PND 35 and trended towards significance (t(12) = 1.782, p = 0.047; Figure 3-9A). For male 
HET and WT mice there were no differences in lateral ventricle to WBV ratio at a single time 
point or between time points for each genotype (Figure 3-9B). For male WT, female HET, and 
female WT mice, lateral ventricle to WBV ratio increased over time (Figure 3-9). Female HET 
mice had higher lateral ventricle to WBV ratios than female WT mice at all time points (Figure 
3-9A). Male HET mice demonstrated lateral ventricle to WBV ratio growth from PND 35 to 49, 
with a subsequent decline on PND 63 (Figure 3-9B). 
 
Figure 3-9. Mean lateral ventricle to whole brain volume ratio ± SD of A. WT and GCPII+/- 
heterozygous (HET) females and B. WT and GCPII+/- heterozygous (HET) males from postnatal day 
35 to 63. Key above each group indicates sex and genotype. Data from the same mice were collected 
over time. Regions were manually traced and volume was calculated using the Region of Interest tool 
on Analyze 10.0. * indicates a significant differences (p < 0.05) between genotypes at a single time 
point as determined with unpaired two-tailed student t-tests assuming unequal variances or a 
significant developmental difference within a genotype and between two time points as determined 
with paired two-tailed t-tests. † indicates a trend towards significant developmental difference between 





Lateral Ventricle Development  
In vivo and post-mortem structural imaging studies have found lateral ventricle 
enlargement in schizophrenia patients compared to controls (Chance et al., 2003; Kempton et al., 
2010; Meduri et al., 2010). Ventricle enlargement was found to be greater in female than male 
schizophrenia patients (Chance et al., 2003). Our findings that female HET mice have 
significantly higher lateral ventricles to WBV ratios than female WT mice on PND 35 agree with 
these findings. Female HET mice also appear to have higher lateral ventricles to WBV ratios on 
PND 49 and 63, but these differences are not significant. Results at these time points require a 
large sample size to reach statistical significance.  
The connection between ventricle enlargement and the biochemical processes in 
schizophrenia remain unclear. Studies suggest that lateral ventricle enlargement occurs either 
from abnormal brain development starting at birth or during the prodromal phase of 
schizophrenia, the period of time from when symptoms manifest to the full development of the 
schizophrenia (Kempton et al., 2010). Ventricular enlargement has been associated with smaller 
cortical and subcortical grey matter volumes (cerebral cortex and neural tissue that comprises the 
outer layer of the cerebrum; Meduri et al., 2010). There is also a possibility that genetic factors, 
such as hereditability, can influence lateral ventricular volume (Reveley et al., 1984).  
Our findings that female WT mice showed significant lateral ventricle to whole brain 
volume ratio growth and that female HET and male WT mice showed non-significant growth 
were expected as the lateral ventricles in healthy individuals and schizophrenia patients are 
expected to grow over time (Kempton et al., 2010). Female HET, male WT mice would likely 
show significant lateral ventricle to WBV ratio growth with a larger sample size as differences 
between time points were apparent but did not reach statistical significance.  
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Lateral Ventricle Asymmetry Results 
Lateral ventricle asymmetry was measured by determining the ratio between left and 
right lateral ventricle volumes. Values that deviated from 1 indicated asymmetry where one 
ventricle was larger than the other. For male and female groups, HET and WT mice showed no 
significant difference in lateral ventricle symmetry at a single time point or between time points 
for each genotype (Figure 3-10). For female HET mice, asymmetry increased over time (Figure 
3-10A).  It should be noted that the standard deviations were very large for most groups of mice 
at all time points, so that differences that were apparent were not statistically significant. 
 
Lateral Ventricle Asymmetry  
Schizophrenia patients are known to exhibit lateral ventricle asymmetry where the left 
lateral ventricle is larger than the right (Chance et al., 2002; Petty, 1999). However, the opposite 
Figure 3-10. Mean left to right lateral ventricle volume ratio ± SD of A. wild-type (WT) and GCPII+/- 
heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Key above each 
group indicates sex and genotype. Data from the same mice were collected over time. Regions were 
manually traced and volume was calculated using the Region of Interest tool on Analyze 10.0. 
Asterisks indicate significant differences (p < 0.05) as determined with unpaired two-tailed student t-
tests assuming unequal variances. No asterisks indicate a lack of significant findings. 
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has also been found in schizophrenia patients, where the right lateral ventricle is larger than the 
left (Meduri et al., 2010). Previous work in our lab found no difference in lateral ventricle 
asymmetry in male and female HET mice compared to controls (Mu, 2011). While we similarly 
found no difference in lateral ventricle symmetry between HET and WT mice, female HET mice 
exhibit a trend where the left lateral ventricle was larger than the right lateral ventricle. A greater 
sample size is needed to reach statistical significance, as these trends were only apparent and not 
significant. 
 
Hippocampus to Whole Brain Volume Ratio Results 
Male WT (t(10) = 1.812, p = 0.02) and female HET (t(12) = 1.782, p = 0.02) mice 
showed significant increase in hippocampus to WBV ratio from PND 35 to PND 63 (Figure 3-7). 
There was a trend towards significance where female WT mice showed an increase in 
hippocampus to WBV ratio from PND 35 to PND 63 (t(12) = 1.782, p = 0.053; Figure 3-7A). 





Hippocampal asymmetry was measured by determining the ratio between left and right 
hippocampus volumes (Figure 3-8). Values that deviated from 1 indicated asymmetry, where one 
side of the hippocampus was larger than the other. Male HET mice had significantly greater 
asymmetry in hippocampi compared to male WT mice on PND 49 (t(8) = 1.860, p < .01; Figure 
3-8B) . For all time points, male HET mice show greater hippocampi asymmetry than male WT 
mice (Figure 3-8B). Conversely, female WT mice showed greater hippocampi asymmetry than 
female HET mice at all time points (Figure 3-8A).  
Figure 3-7. Mean hippocampus to whole brain volume ratio ± SD of A. wild-type (WT) and GCPII+/- 
heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Key above each 
group indicates sex and genotype. Data from the same mice were collected over time. Regions were 
manually traced and volume was calculated using the Region of Interest tool on Analyze 10.0. * indicates 
significant developmental difference (p < 0.05) within a genotype and between two time points as 
determined with paired two-tailed t-tests. † indicates a trend towards significant developmental difference 





Hippocampus Development and Asymmetry 
The hippocampus is known to exhibit abnormal function and structure in schizophrenia 
patients. Altered synaptic wiring from the hippocampus to extrinsic connections is hypothesized 
to alter glutamatergic pathways (Harrison, 2003). Further, hippocampal abnormalities have been 
linked to neuropsychological impairments (Harrison, 2003; Heckers, 2001). For example, small 
hippocampal size is correlated to poor premorbid adjustment, a rating scale that evaluates the 
degree of achievement of developmental goals at several points of a subject's life before the 
onset of schizophrenia (Smith et al., 2003). 
Hippocampus to WBV ratios significantly increased from PND 35 to 63 for male WT, 
and female HET mice, and trended toward significance for female WT mice. This was expected 
and considered an effect of normal brain growth. Male HET mice, the one group that did not 
show a significant increase from PND 35 to 63, would likely reveal significant differences with a 
Figure 3-8. Mean left to right hippocampus volume ratio ± SD of A. wild-type (WT) and 
GCPII+/- heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. 
Key above each group indicates sex and genotype. Data from the same mice were collected over 
time. Regions were manually traced and volume was calculated using the Region of Interest tool 
on Analyze 10.0. * indicates a significant difference (p < 0.05) between genotypes at a single time 
point as determined with unpaired two-tailed t-tests assuming unequal variances.  
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larger sample size as the growth is apparent but not significant. Studies have found reduced 
hippocampal volume in schizophrenia patients compared to controls (Chance et al., 2001; 
Harrison, 2003; Heckers, 2001; Tsai et al., 2002). Previous work in our lab also found 
hippocampus to WBV ratio to be decreased at PND 77 in male and female HET mice compared 
to controls (Mu, 2011). Our results that HET males had non-significantly smaller hippocampus 
to WBV ratios than WT males on PND 49 and 63 agree with these findings. However, these 
results require a large sample size to reach statistical significance.  
Hippocampal asymmetry is hypothesized to develop from asymmetric neural 
development (Harrison, 2003). Structural imaging studies have found hippocampal asymmetry 
where the left hippocampus is smaller than the right hippocampus in schizophrenia patients 
compared to controls (Harrison, 2003; Heckers, 2001). Previous works in our lab have found the 
left to right hippocampus ratio in male and female HET mice to be higher than controls (Mu, 
2011). We found that male HET mice had significantly greater left to right hippocampus ratios 
compared to male WT mice on PND 49 and non-significantly greater ratios compared to WT 
mice on PND 35 and 63. Our findings agree with the previous studies in terms of identifying 
asymmetry. However, we found the opposite asymmetry than human studies. More studies on 
how the left and right hemispheres of a mouse brain correspond to the left and right side of a 
human brain would help elucidate our results.  
The significant increase in asymmetry from PND 35 to 49 for male HET mice could be 
indicative of disease progression. Interestingly, results from the female group differ from those 
in males, where female WT mice exhibited a trend of greater asymmetry than female HET mice 
at all time points. These trends are apparent at PND 35 and 49 for female mice and on PND 49 
and 63 for male mice, but are not significant. Our results on hippocampal asymmetry would be 
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more conclusive if consistent significance differences could be identified at multiple time points. 
Data from a larger sample size or later time points may reveal these differences.  
 
Individual Volume Trends 
Volume trends for one mouse of each genotype and sex from the same litter were 
examined to determine individual volume trends. Mouse 459 (WT-M), 458 (HET-M), 463 (WT-
F), 462 (HET-F) from Litter 77 were used for this analysis (Figure 3-11). Third ventricle volume 
was different for HET and WT genotypes (Figure 3-11E). At all time points, male and female 
HET mice in this litter had larger third ventricle volumes than male and female WT mice (Figure 
3-11E). An enlarged third ventricle is a known characteristic of schizophrenia patients compared 
to controls (Nakamura et al., 2004; Shenton et al., 2001; Tsai et al., 2002). These differences 
were not apparent at all time points when data from several mice were combined, which suggest 
there may be a litter effect. This is possible, as the volume of certain brain structures, such as the 




Figure 3-11. Volume of brain structures for a wild-type (WT)-male (M), GCPII+/- heterozygous 
(HET)-M, WT-F, and HET-F mouse (459, 458, 463, 462) from PND 35 to 63. All mice were from the 
same litter (77). Regions analyzed were A. Whole brain (WB) B. Cerebellum (C) C. Hipocampus (HP) 
D. Lateral ventricles (LV) E. third ventricle (3V) F. fourth ventricle (4V) G. Left to right hippocampus 
ratio (L/R HP) H. Left to right lateral ventricle ratio (L/R LV). Key on the bottom right indicates 
genotype and sex of each mouse. Regions were manually traced and volume was calculated using the 
Region of Interest tool on Analyze 10.0.  
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Summary of MRI Findings  
- * Sex differences were found in cerebellum/WB for HET and WT mice and hippocampi 
asymmetry for HET mice 
- HET and WT mice exhibited similar development in WBV and hippocampus to WBV 
ratio 
- WBV was significantly greater for female HET mice compared to female WT mice at 
PND 63.  
- Cerebellum to WBV ratio was significantly higher in male HET mice than male WT at 
all time points, but was only significant on PND 63. Cerebellum to WBV was 
significantly higher in female WT mice compared to female HET mice, but was only 
significant on PND 63.  
- * Fourth ventricle to WBV ratio was significantly higher in male HET mice than male 
WT mice on PND 49  
- * Third ventricle to WBV ratio was significantly higher in female HET mice than female 
WT mice on PND 35 
- * Lateral ventricle to WBV ratio was greater in female HET mice than female WT mice 
at all time points, but was only significant on PND 35 
- * Hippocampi asymmetry was greater in male HET mice than male WT mice at all time 
points, but only significant on PND 49 
 
An * indicates findings that were consistent with literature results for schizophrenia patients 
compared to controls.  
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3.2  Magnetic Resonance Spectroscopy  
MRS data were collected from a 4x3x2 mm3 (24 µL) voxel positioned on the 
hippocampus in same HET males (n = 2), WT males (n = 6), HET females (n = 7), and WT 
females (n = 7) on PND 35/36, 49/50, and 63/64. Two of the HET males used for MRI data 
could not be used for MRS data due to instrument difficulties that occurred at one time point. 
Metabolite peak areas were divided by the area of Cr (3.0 ppm), an internal standard, and 
averaged for each time point. The metabolite ratios of (NAA+NAAG)/Cr, Tau/Cr, Cho/Cr, and 
Glx/Cr were analyzed (Table 3-2). 
 
Sexual Dimorphism 
Metabolite differences between male and female mice were examined in HET and WT 
brain structures (Figure 3-12 and 3-13). Cho/Cr ratios were lower in HET males than females on 
PND 49 (t(7) = 1.895, p = 0.02; Figure 3-12C). This contrasts with a study by Buckley et al. 
(1994) that found male schizophrenic patients have less NAA and more Cho in the frontal cortex 
compared to male controls and female schizophrenia patients, but this study looked at a different 
brain structure. No differences were found between male and female WT mice (Figure 3-13). 
These findings agree with a study by Charles et al. (1994) that found no differences in Cho or 
NAA levels between males or females in grey or white matter. No studies report differences in 
Tau and Glx metabolite levels between male and female humans or mice.  
Our MRS findings, in conjunction with volume data, are supportive of sex differences 
between male and female mice. In order to control for sex differences, all MRS analyses were 






Figure 3-12. Mean metabolite concentration ratio ± SD between GCPII+/- heterozygous (HET) males (M) and 
females (F) from postnatal day 35 to 63. A. Glutamate and Glutamine/Creatine concentration ratio (Glx/Cr), B. 
Taurine/Crconcentration ratio (Tau/Cr), C. Choline/Cr concentration ratio (Cho/Cr), D. N-acetylaspartate and N-
acetylaspartylglutamate/Cr (NAA+NAAG/Cr). Key on the bottom indicates sex and genotype. Data from the 
same mice were collected over time. Bruker Topspin 1.5 was used to fit a Gaussian peak underneath each 
metabolite peak and quantify metabolite concentration. * indicates a significant difference (p < 0.05) as 






Figure 3-13. Mean metabolite concentration ratio ± SD between GCPII+/- wild-type (WT) males (M) and 
females (F) from postnatal day 35 to 63. A. Glutamate and Glutamine/Creatine concentration ratio (Glx/Cr), 
B. Taurine/Crconcentration ratio (Tau/Cr), C. Choline/Cr concentration ratio (Cho/Cr), D. N-acetylaspartate 
and N-acetylaspartylglutamate/Cr (NAA+NAAG/Cr). Key on the bottom indicates sex and genotype. Data 
from the same mice were collected over time. Bruker Topspin 1.5 was used to fit a Gaussian peak 
underneath each metabolite peak and quantify metabolite concentration. * indicates a significant difference 
(p < 0.05) as determined with unpaired two-tailed student t-tests assuming unequal variances. No * indicates 




Our MRS findings, in conjunction with volume data, are supportive of sex differences 
between male and female mice. In order to control for sex differences, all MRS analyses were 




N-acetylaspartate and N-acetylaspartylglutamate to Creatine Results 
 
(NAA+NAAG)/Cr ratios in the hippocampus of male HET mice were higher than for 
male WT mice on PND 35 and trended towards significance (t(6) = 1.943, p = 0.048; Figure 3-
14B). At all time points, male HET mice had higher ratios of (NAA+NAAG)/Cr compared to 
male WT mice but they were not significant at later time points. Female WT, female HET, and 
male WT mice exhibited non-significant increases in (NAA+NAAG)/Cr ratios over time (Figure 
3-14). For female mice, no significant differences were found at any time point or between time 
points for either genotype (Figure 3-14A). 
Table 3-2. MRS metabolite data for male WT, male HET, female WT, and female HET mice. A. * 
indicates a significant difference between WT and HET mice at that time point (p < 0.05). † indicates 
a trend towards significance between WT and HET mice (0.05 < p < 0.07). B. * indicates a significant 
developmental difference between indicated time points within a genotype and sex (p < 0.05). † 




NAA and NAAG levels in HET mice compared to Schizophrenia Patients 
Studies on NAA in schizophrenia patients have found reduced levels in the hippocampus 
(Bertolino et al., 1997; Deicken et al., 1998; Nasrallah et al., 1994; Pegues et al., 2000; Steen et 
al., 2005) and reduced ratios of NAA/Cr in the left hippocampus (Deicken et al., 1998; Miyaoka 
et al., 2004). The opposite has also been found, where NAA levels were found to be higher in the 
hippocampus of schizophrenia patients compared to controls (Lutkenhoff et al., 2010). Previous 
work in our lab also found no differences in (NAA+NAAG)/Cr ratios in the hippocampus of 
male and female HET mice compared to controls (Mu, 2011). These results disagree with our 
findings, but this is not surprising as males and female data were analyzed separately in this 
study. Few studies have examined the combined ratio NAA and NAAG to Cr in the 
hippocampus. Our study that analyzed ex vivo metabolite levels in the cortex of the same mouse 
model (GCPII+/- HET) found no effect of genotype on (NAA+NAAG)/Cr compared to controls 
Figure 3-14. Mean N-acetylaspartate and N-acetylaspartylglutamate/creatine (NAA+NAAG/Cr) concentration 
ratio ± SD between A. wild-type (WT) and GCPII+/- heterozygous (HET) females and B. WT and HET males 
from postnatal day 35 to 63. Keys above graphs indicate sex and genotype. Data from the same mice were 
collected over time. Bruker Topspin 1.5 was used to fit a Gaussian peak underneath each metabolite peak and 
quantify metabolite concentration. * indicates a significant difference (p < 0.05) as determined with unpaired 
two-tailed student t-tests assuming unequal variances.  
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(Schaevitz et al., 2011). Another study by Tsai et al. (1995) reported increased levels of NAAG 
in the hippocampus, but no significant changes of NAA in schizophrenia patients compared to 
controls. Additionally, Kegeles et al. (2000) and Sigmundsson et al. (2003) found no abnormal 
NAA levels in the hippocampus of schizophrenia patients compared to controls.  
We found that male HET mice had higher ratios of (NAA+NAAG)/Cr that trended 
towards significance on PND 35 and non-significantly higher ratios of (NAA+NAAG)/Cr on 
PND 49 and 63 compared to male WT mice. These findings strongly support studies that report 
increased levels of NAA (Lutkenhoff et al., 2010) or increased levels of NAAG (Tsai et al., 
1995) with slightly decreased (Bertolino et al., 1997; Deicken et al., 1998; Nasrallah et al., 1994; 
Miyaoka et al., 2004) or no changes (Kegeles et al., 2000; Sigmundsson et al. (2003); Tsai et al., 
1995) in levels of NAA in the hippocampus of schizophrenia patients compared to controls. 
Increased levels of NAAG and proportionally smaller decreased levels of NAA in male HET 
mice compared to controls are most consistent with reduced GCPII enzyme function as GCPII is 
responsible for cleaving NAAG into NAA and Glu. We could not confirm or reject other 
combinations of increased, decreased, or lack of change in levels of NAA and NAAG as these 
metabolites could not be separately resolved in our spectra.  
NMDAR hypofunction, the basis of the glutamate hypothesis, arises from a combination 
of reduced glutamate release and increased NMDAR antagonism by NAAG. Elevated levels of 
NAAG would suggest increased NMDAR inhibition and decreased levels of NAA may reflect 
decreased neuronal density or hypometabolism in schizophrenia patients compared to controls 
(Bracken et al., 2011). Thus our findings are consistent with the glutamate hypothesis if 
increased ratios of (NAAG+NAA)/Cr in the hippocampus correspond to increased levels of 
NAAG and decreased levels of NAA. These results were unexpected as we hypothesized that 
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HET mice would exhibit increased levels of NAAG, with an even greater reduction in levels of 
NAA such that (NAA+NAAG)/Cr would be reduced.  
Our findings are interesting as they contribute to findings of NAA abnormalities in 
schizophrenia patients compared to controls. Differences in (NAA+NAAG)/Cr levels between 
male HET and WT mice on PND 35, 49, and 63 were apparent, yet not significant. A larger 
sample size would be needed to attain statistical significance. Further, the ability to resolve NAA 
and NAAG separately would also make our results more conclusive.  
 
Taurine to Creatine Results 
 
Tau/Cr ratios significantly decreased from PND 35 to 63 for female HET mice (t(12) = 
1.782, p = 0.0248; Figure 3-15A). For male mice, no significant differences were found at any 
time point or between time points for either genotype (Figure 3-15B). 
 
Figure 3-15. Mean taurine/creatine (Tau/Cr) concentration ratio ± SD between A. wild-type (WT) and 
GCPII+/- heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Keys 
above graph indicate sex and genotype. Data from the same mice were collected over time. Bruker 
Topspin 1.5 was used to fit a Gaussian peak underneath each metabolite peak and quantify metabolite 
concentration. * indicates a significant difference (p < 0.05) as determined with unpaired two-tailed 
student t-tests assuming unequal variances.  
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Developmental Changes in Tau 
Few studies have reported abnormalities in Tau levels in the hippocampus of 
schizophrenia patients. One study that examined metabolite levels in the medial prefrontal cortex 
found increased levels of Tau in schizophrenia patients compared to controls (Shirayama et al., 
2010). Interestingly, we found that Tau levels in male HET mice significantly decreased from 
PND 35 to 63. A similar result was previously found in our lab, where male and female WT mice 
exhibited a significant decrease in Tau levels from PND 35 to PND 63 (Mu, 2011). A larger 
sample size would likely reveal similar findings for the WT mice in this study. These results 
suggest that HET mice reflect behavior of WT mice and that Tau/Cr ratios may not be a useful 
indicator of schizophrenia. Alternatively, Tau abnormalities in schizophrenia patients may exist, 
but our results are limited by our ability to resolve the Tau peak.  
 
Choline to Creatine Results 
Female HET and WT mice exhibited significant changes in Cho/Cr ratios over time 
(Figure 3-16A). Female HET mice showed a significant increase in Cho/Cr ratios from PND 35 
to 63 (t(12) = 1.782, p = 0.0183) and PND 35 to 49 (t(12) = 1.782, p = 0.0006), and a significant 
decrease from PND 49 to 63 (t(12) = 1.782, p = 0.0323; Figure 3-16A). Female WT mice 
showed an increase in Cho/Cr ratios from PND 35 to 63 (t(12) = 1.782, p = 0.0076) and 35 to 49 
(t(12) = 1.782, p = 0.0086; Figure 3-16A). Male HET mice exhibited a trend of increased Cho/Cr 
ratios over time (Figure 3-16B).  
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Developmental Changes in Cho 
Studies disagree on how Cho levels are affected in the hippocampus of schizophrenia 
patients. Reduced (Maier et al., 1995), increased (Lutkenhoff et al., 2010), and unchanged 
(Deicken et al., 1998; Delamillieure et al., 2002) levels of Cho have been found in the 
hippocampus of schizophrenia patients compared to controls. Our finding that there are no 
differences between HET and WT mice agrees with studies that propose no Cho abnormalities in 
the hippocampus of schizophrenia patients compared to controls. This is further confirmed by 
our finding that female WT and HET mice exhibit similar development trends from PND 35 to 
49 and PND 35 to 63. Few studies have conducted longitudinal assessment of metabolite levels 
in schizophrenia over time. Previous work in our lab found an increase in Cho/Cr levels from 
PND 35 to 49 in male and female WT mice (Mu, 2011). However, the implications of this 
Figure 3-16. Mean choline/creatine (Cho/Cr) concentration ratio ± SD between A. wild-type (WT) and 
GCPII+/- heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 63. Data from the 
same mice were collected over time. Bruker Topspin 1.5 was used to fit a Gaussian peak underneath each 
metabolite peak and quantify metabolite concentration. * indicates a significant difference (p < 0.05) as 
determined with unpaired two-tailed student t-tests assuming unequal variances. †indicates a trend towards a 
significant difference between genotypes at a single time point (0.05 < p < 0.07). 
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change are unclear (Mu, 2011). The changes in Cho levels observed in females could reflect 
specific changes in the development of neural membrane composition. The lack of difference 
between HET and WT mice shows that phospholipid membrane turnover is not changed in 
schizophrenia. This confirms that schizophrenia is a neurodevelopmental, not neurodegenerative, 
disorder.  Based on our findings, Cho/Cr ratios are not a good indicator of schizophrenia. 
 
Glutamate and Glutamine to Creatine Results 
There were no significant differences found for Glx/Cr ratios at any time point or 




Figure 3-17. Mean glutamate and glutamine/creatine (Glx/Cr) concentration ratio ± SD between A. wild-
type (WT) and GCPII+/- heterozygous (HET) females and B. WT and HET males from postnatal day 35 to 
63. Keys above graphs indicate sex and genotype. Data from the same mice were collected over time. 
Bruker Topspin 1.5 was used to fit a Gaussian peak underneath each metabolite peak and quantify 
metabolite concentration. * indicates a significant difference (p < 0.05) as determined with unpaired two-
tailed student t-tests assuming unequal variances. No asterisks indicate the lack of significant findings. 
 
 66 
Glx and Relevance to the Glutamate Hypothesis 
 
Glx or Glx/Cr ratios were found to be increased (Chang et al. 2007), decreased 
(Ohrmannet al., 2007), and the same (Bustillo et al., 2001, Wood et al., 2008) in various brain 
structures (white matter, prefrontal cortex, broad brain region, and hippocampus) of 
schizophrenia patients compared to controls. Previous work that combined male and female data 
found complex trends in Glx/Cr ratios where HET mice had higher Glx/Cr ratios than WT mice 
on PND 63 and Glx/Cr levels significantly increased from PND 49 to 63 for HET mice (Mu, 
2011). Our finding, that there were no differences in Glx/Cr ratios between HET and WT mice, 
contrasts with previous work, yet supports studies that found no differences in Glx/Cr ratios 
between schizophrenia patients and controls. Our study that analyzed ex vivo metabolite levels in 
the cortex of the same mouse model (GCPII+/- HET) similarly found no effect of genotype on 
Glx/Cr ratios (Schaevitz et al., 2011).  
The glutamate hypothesis is based on NMDAR hypofunction, which is caused by 
reduced Glu and increased NMDAR antagonism by NAAG. We expected Glx/Cr ratios to be 
reduced in HET mice compared to controls to reflect decreased levels of Glu, as Tsai et al. 
(1995) found Glu levels were reduced in the hippocampus of schizophrenia patients compared to 
controls. However, we found Glx/Cr ratios to remain unchanged between genotypes. These 
results were not surprising as Glu and Gln are separately affected in schizophrenia. Glx is a 
combined measurement of the metabolites of Glu and Gln and reflects the total glutamatergic 
pool available for synaptic–metabolic activity while separate levels of Glu and Gln reflect their 
respective distribution in neuronal and glial cells (Yuksel and Ongur, 2005). Though Glx/Cr 
ratios remained the same, it was possible that the proportions of Glu to Gln were different 
between genotypes.  
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Schaevitz et al. (2011) found the Glu to Gln ratio was significantly increased by 15% in 
the cortex of HET mice compared to controls, but determined no difference in Glu/Cr or Gln/Cr 
levels. The increased Glu to Gln ratio was hypothesized to occur from a decrease in glutamine 
levels rather than a change in glutamate levels (Shaevtiz et al., 2011). An increased Glu/Gln ratio 
reflects reduced glutamatergic neurotransmission, as Gln is a precursor to Glu (Yuksel and 
Ongur, 2005). Glutamate-glutamine cycles that reflect this imbalance have been found in rodents 
given NMDAR antagonists (Schaevitz et al., 2011). This is promising as GCPII regulates 
NMDAR function and NMDAR antagonists in normal individuals mimic the biochemical 
pathways of schizophrenia. 
Few studies have specifically examined Glu and Gln in the hippocampus, which makes it 
difficult to compare our results.  Further, there is a wide range of possibilities for the Glu to Gln 
ratio in HET mice compared to controls. Given what previous studies have found, our results 
support an increased Glu/Gln ratio, which aligns with reduced GCPII function. The ability to 
separately resolve Glu and Gln would likely make our results more conclusive as changes in 
these metabolite levels are an indirect way of determining NMDAR function.  
 
Individual Metabolite Level Trends 
Metabolite/Cr trends for four mice, one mouse of each genotype and sex, from the same 
litter were examined (Figure 3-18). Mouse 459 (WT-M), 458 (HET-M), 463 (WT-F), 462 (HET-
F) from Litter 77 were used for this analysis. These were the same mice used to investigate 




Female HET and WT mice had higher Tau/Cr levels than male HET and WT mice at all 
time points (Figure 3-18B), suggesting a sex difference. No studies could be found that reported 
sex differences in Tau or Tau/Cr levels in humans or mice. Tau acts as a neuroprotectant and 
levels of Tau are hypothesized to elevate in response to increased oxidative stress. The release of 
different sex hormones may result in synaptic wiring that alters stress responses, thereby 
affecting Tau levels.  
Figure 3-18. Metabolite/creatine (Cr; 3.0 ppm) levels in the hippocampus of a wild-type (WT)-male 
(M), GCPII+/- heterozygous (HET)-M, WT-F, and HET-F mouse (459, 458, 463,462) from PND 35 to 
63. All mice were from the same litter (77). Metabolites analyzed were A. Glutamine and Glutamate 
(Glx) /Cr B. Taurine (Tau)/Cr C. Choline (Cho)/Cr D.  Key on the bottom indicates genotype and sex of 
each mouse.  Bruker Topspin 1.5 was used to fit a Gaussian peak underneath each metabolite peak and 
quantify metabolite concentration.  
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Female HET and WT mice had higher Cho/Cr levels than HET and WT males at all time 
points (Figure 3-18C). These findings agree with a study by Buckley et al. (1994) that found 
male schizophrenic patients had less NAA and more Cho in frontal cortex compared to female 
patients. 
Male HET and WT (NAA+NAAG)/Cr levels were slightly greater than those of female 
HET and WT mice on PND 49 (Figure 3-18D). This contrasts with a study by Charles et al. 
(1994) that found no differences in NAA levels between males and females, and a study by 
Buckley et al. (1994) that found male schizophrenic patients had less NAA in frontal cortex 
compared to female patients. However, it is difficult to align our results with these findings as we 
examined a different brain region and could not resolve NAA and NAAG separately.  
Glx/Cr trends were the least clear. The female HET mouse appeared to have a much 
lower Glx/Cr than all other mice at all time points (Figure 3-18A). This was interesting, as no 
studies have reported differences in Glx metabolite levels between male and female humans or 
mice. 
All observed differences were not apparent when data from several mice were combined, 
suggesting a litter effect. With a larger sample size, it would be possible to see if characteristics 
of schizophrenia are affected by litter differences.  
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Summary of MRS Findings 
- Sex differences were found in Cho/Cr ratios for HET mice 
- There were no significant differences between HET and WT mice in NAA/Cr, Cho/Cr, 
Tau/Cr or Glx/Cr ratios at any time point 
- HET and WT mice exhibited similar development in Cho/Cr ratios 
- Tau/Cr levels significantly decreased from PND 35 to 63 for female HET mice. 
- (NAA+NAAG)/Cr ratios were greater for male HET mice than male WT mice at all time 
points and trended towards significance on PND 35. 
 
While MRS findings did not reveal significant differences between genotypes, we found 
interesting developing trends that may be attributed to reduced GCPII function. 
 
4  General Conclusions and Future Work 
In this study, we found distinct morphological, neurochemical and sex differences in 
HET mice compared to WT mice. Volume data showed HET mice to exhibit asymmetric 
hippocampi and enlarged ventricle (fourth, third, and lateral) to WBV ratios. Metabolite data 
showed apparent differences in (NAA+NAAG)/Cr levels, but no significant effect of genotype 
on (NAA+NAAG)/Cr, Cho/Cr, Tau/Cr, or Glx/Cr ratios. Sex differences were found in 
cerebellum to WBV ratios of HET and WT mice, and hippocampus asymmetry and Cho/Cr 
levels in HET mice. Future work should increase the sample size such that differences between 
genotypes are significant at multiple time points. Later time points may also reveal distinct 
differences between genotypes. This is especially true for volume data, as certain brain structures 
may exhibit progressive growth or delayed, abnormal growth in schizophrenia patients. It is also 
possible that the mutation in this mouse model does not reflect all morphological and 
neurochemical characteristics of schizophrenia in humans. 
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There are other factors that may have contributed to fewer than expected significant 
differences. Difficulties in tracing may have caused large standard deviations in the volume data, 
as certain structures, such as the hippocampus and lateral ventricles, were difficult to trace if the 
outline of the structure was not apparent. For metabolite data, the Glx and (NAA+NAAG) peak 
each represented two metabolites, Glu and Gln and NAA and NAAG, respectively. The ability to 
separately resolve Glu, Gln, NAA, and NAAG would allow us to determine the exact 
concentration of each metabolite and make our results more conclusive. In the future, ex vivo 
studies could compare metabolite levels in the hippocampus of HET mice compared to controls. 
It would also be interesting to see how ex vivo data from the hippocampus compare to in vivo 
results from the cortex and ex vivo data from the cortex (Schaevtiz et al., 2011).  
Results from individual volume and metabolite ratio trends indicated the possibility of 
litter effects. Future work should investigate these effects by quantifying individual brain volume 
or metabolite ratios of mice in the same litter with the same sex and genotype for each time 
point. Additionally, it would also be interesting to see if the litter effects are related to weight, as 
mice in the same litter tend to be in the same weight range. 
Our findings from this study are exciting, as they show that the GCPII+/- mouse model 
mimics several of the characteristics of schizophrenia and that reduced GCPII function replicates 
certain aspects of the biochemical pathways in schizophrenia. This study has widened our 
understanding of the morphological and neurochemical abnormalities that may arise from 
reduced GCPII function in schizophrenia. With a greater sample size, this mouse model has the 
potential to test treatments that focus on the glutamatergic pathways of schizophrenia, offering 
help to those affected by this debilitating psychiatric disorder. 
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Appendix A: Tracing Guide 
  
This guide should be used as a reference for tracing structures in a mouse brain. Below 
are twenty-one contiguous slices, or images, of a male HET mouse brain on PND 35. Each 
image is labeled with a number and as the number increases, the images go from posterior (back) 
to anterior (front) of the brain. Notes on tracing appear underneath the images. Some regions 
may be difficult to trace due to lack of distinction or outline, thus it may be necessary to refer to 
a mouse brain atlas and/or use your best judgment. When tracing, the most important thing to 
remember is to be consistent in how you define a region.  
 
Regions of interest were traced using the region of interest tool in Analyze 10.0, image 
analysis software. Each region is outlined by a different color and labeled with an abbreviation 
(Table AA-1) 
 
Table AA-1. Abbreviation and outline color of brain regions and images in which the regions 
were traced.  
 
Brain Region  Abbreviation  Outline Color  Images with the Region 
Whole Brain  WB  Red  All 
Cerebellum  CB  Green  2,3,4,5,6 
Fourth Ventricle  4V  Yellow  3,4,5 
Left Hippocampus  L-HP  Dark Blue  8,9,10,11 
Right Hippocampus  R-HP  Bright Purple  8,9,10,11 
Left Lateral Ventricle  L-LV  Teal  9,10,11,12,13,14 
Right Lateral 
Ventricle  R-LV  White  9,10,11,12,13,14 






Tracing begins in the most posterior slice that the cerebellum can be seen (Image #2). 
The cerebellum is recognizable as it appears striated and rests on top of the brain stem. In slices 
with the cerebellum, the whole brain region is traced as all tissue excluding the cerebellum. 
While this may seem like the cerebellum isn’t part of the whole brain, whole brain volume is 
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calculated as a summation of all regions traced during analysis. The fourth ventricle appears 
white and triangle-shaped (Image #3). 
 
If there are smaller regions to be traced inside a larger region, such as the fourth ventricle 
within the whole brain in Image #3, then the larger region is traced first such that the smaller 
region is not “over-traced” (middle arrow, Image #3). Avoid tracing external areas that appear 







The lobes of the cerebellum, or paraflocculi, appear in Image #4. Occasionally the 
paraflocculi will appear disconnected from the brain, but they should still be traced. In Image #6, 
the colliculi appear and should be traced as part of the whole brain (top arrow). The cerebellum 





The left and right hippocampi appear in Image #8. The left and right lateral ventricles 
appear white in Image #9 and are usually adjacent to the left and right hippocampi, respectively. 
Also in image #9 is the third ventricle down the center; the third ventricle may not appear 
connected. In image #9, the bottom arrows indicate connective tissues that should not be traced. 





Continue tracing the left and right hippocampi, left and right lateral ventricles, and third 
ventricle. Again, the connective tissues that appear triangle-shaped should not be traced. In 
Image #12, the lateral ventricles connect with the third ventricle. In our tracing we defined the 





Continue tracing the left and right lateral ventricles, and third ventricle. Eventually, the 





Continue tracing the whole brain until there is no more brain tissue to trace. Generally, 
there is no more to trace when the eyes are no longer visible (Image #21). 
 
Other important notes (Mu, 2011) 
 
• When tracing, you will often not be able to finish tracing an entire region without lifting 
the pen. When adding to the region, use the edit tool; do NOT continue using the trace 
tool. Otherwise when the area is being calculated a chunk will be missing in the middle 






• The “undo” button is near the bottom of the window. Pressing Ctrl + Z does not work. 
• The “delete button” is near the undo button, and is a picture of a trash can. 
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• Pressing “Esc” on the keyboard will force quit the ROI window, and deletes any unsaved 
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Appendix B: The R168X Mouse Model of Rett Syndrome and Viability 
 
Rett syndrome (RTT) is a neurodevelopmental disorder that is the second leading cause 
of mental retardation in girls. RTT is primarily caused by a random mutation in the X-linked 
gene that encodes methyl-CpG-binding protein 2 (MeCP2; Rett Syndrome Fact Sheet, 2007). 
MeCP2 specifically binds to methylated DNA and regulates the transcription of other genes. If 
MeCP2 is mutated, insufficient or abnormal amounts of MeCP2 are produced which leads to 
irregular expression of these regulated genes (Chen, 2001). The effects of the mutation are 
severely debilitating; symptoms of RTT, such as breathing abnormalities, are often responsible 
for premature deaths. There is no cure for RTT and effective treatments are limited because early 
diagnosis is difficult.  
Previous work in this lab attempted to establish early detection and monitoring methods 
for RTT treatment development by investigating, in vivo, the longitudinal brain morphology and 
neurochemical profile of MeCP2R168X , a mouse model of RTT (Huang, 2011). These mice are 
unique in that they have R168X, one of the most common mutations in patients with RTT, 
knocked into the Mecp2 gene. The Mecp2R168X mouse model exhibits many features similar to 
RTT, such as hypoactivity, forelimb stereotypies, breathing irregularities, weight changes, hind 
limb atrophy, scoliosis, and a reduction in UBE3A RNA and protein products (Lawson-Yuen, 
2007).  
 
Through a longitudinal study on the MeCP2R168X mouse model, we hoped to better 
understand the developmental and neurochemical basis of RTT to identify, monitor, and treat 
RTT. We hypothesized that our findings on the MeCP2R168X mouse model would reflect studies 
conducted on RTT patients and other mouse models of RTT. However, breeding and breathing-
related complications arose that prompted us to terminate this study. 
 
The non-invasive techniques of Magnetic Resonance Imaging (MRI) and Spectroscopy 
(MRS) were used to examine male mutated (null) and normal (wild-type; WT) mice on postnatal 
days (PND) 21, 28, 35, and 49. In this study, only male mice were examined because null male 
mice exhibit more severe symptoms of RTT compared to the mutant, or heterozygous, female 
counterparts. MRI allowed us to visualize brain structures and quantify their volumes, which 
reflect neural development. With MRS, we determined neurometabolite concentrations, whose 
levels are known to be indicators of neuronal health. MRS data were collected from the 
hippocampus, a region in the brain known to function differently in RTT patients.  
 
In early experiments, breathing abnormalities were observed- null mice exhibited shallow 
breathing or would cease breathing for brief intervals. Over time, breathing abnormalities in the 
new litters were more severe. Mice are normally sensitive to the isoflurane, where a slight 
decrease or increase in % isoflurane/O2 gradually causes breaths per minute (bpm) to increase or 
decrease, respectively. However, null mice appeared to be hypersensitive to isoflurane increases, 
but resistant to decreases. For example, if isoflurane/O2 levels were increased slightly, bpm 
would plummet, but when isoflurane/O2 levels were decreased, bpm would remain constant or 
continue to fall. Null mice survived the two hour-long experiments, but ceased breathing post-
anesthesia during recovery on a heating pad. When the mice were genotyped, it was determined 
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that all the mice that had died were null. The cause of death was likely related to breathing 
abnormalities from the MeCP2 mutation combined with stress and isoflurane exposure.  
Plasma levels of epineprhine are known to increase in isoflurane-anesthesized in 
MeCP21lox mice, a different MeCP2 deficient model, compared to controls (Ladas et al., 2009). 
Ladas et al. (2009) hypothesized that this hypersecretory phenotype may alter the sensitivity of 
MeCP2 null mice to stress. Our experiments found that null mice exhibited an exaggerated 
response to stress compared to control, which confirms these findings.  
Upon consultation with the Wellesley College veterinarian, Dr. Lynn Jackson, it was 
determined that the R168X mutation was becoming more severe as the mice exhibited more 
genetic homogeneity. Backcrossed mice older than six generations began to exhibit almost 
exclusively homozygous or hetereozygous characteristics (Figure AB-1). Our null mice were 
backcrossed for approximately six generations and were congenic to heterozygous mice at the 
loci of the R168X mutation. 
 
 
Figure AB-1. Genomic homogeneity and heterogeneity during the creation of a congenic strain.  
The reciprocal points on each line indicate the percentage of loci in the genome of each 
individual animal that will be homozygous for the inbred partner allele or heterozygous with the 
donor allele at each generation backcrossing. Adapted from Wellesley College Animal Care 
Facility Manual (2011). 
Interestingly, a congenic strain is usually desirable, as homozygous and heterozygous 
mice would be 100% different at the loci of the R168X mutation and could be compared for 
phenotypic differences. However, as the loci became more homozygous in null mice, viability 
declined. Attempts to maintain loci percentage below 100% would have been ideal to maintain 
viability, but not feasible. Even if the homozygous mice were outbred to a different strain of WT 
mice to reduce percentage homozygous loci, the mice would have shortly returned to genetic 
homogeneity after several backcross generations.  
Several measures were taken to prevent mouse death. The PND 21 imaging date was 
removed to limit the amount of stress experienced in one day, as mice were also weaned, or 
removed from the mother into a separate cage, on PND 21. Isoflurane levels were kept as low as 
possible so that bpm would not plummet, however bpm fell even with low levels of isoflurane. 
Resuscitation techniques were also attempted on mice that stopped breathing during recovery. 
 87 
The plunger of a syringe was removed and the narrow end of the syringe was inserted into the 
mouse mouth. The large and open end of the syringe was used to blow small puffs of air into the 
mouse’s mouth. This technique was not successful, as it was difficult to insert the syringe into 
the mouse’s mouth. Further, even if the syringe was thoroughly inserted, there was no seal to 
direct the air into the mouse’s lungs.  
As the experiments continued, it also became apparent that MeCP2R168X litters produced 
few progeny and fewer males than females; there were approximately two males in every litter. 
The cause of these problems were unknown, but likely related to the more severe symptoms 
experienced by male null mice compared to heterozygous female mice. These breeding problems 
made it difficult to collect data with a sample size large enough for analysis.  
 
The R168X mutation is one of the most common mutations found in human RTT patients 
and causes the most severe symptoms. These human symptoms relate to the breathing and 
breeding abnormalities issues found in the MeCP2R168X mouse model. The origins of these 
problems were thought to be associated to a hypersensitive stress response to isoflurane and null 
mice exhibiting genomic homogeneity. Attempts were made to reduce the stress-related 
breathing problems, but they were unsuccessful as the mice continued to die post-anesthesia. 
Given the inability to collect data due few male progeny and sudden post-anesthesia deaths, we 
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Appendix C: Development of a “Green” MRI Phantom 
 
A phantom is an object that can hold NMR tubes to assess the image intensity of 
solutions in MRI experiments. Traditionally, these phantoms were made by suspending three 
NMR tubes in a large conical tube using agarose, a gel-like material (Figure AC-1). The 
phantom was then wrapped with paper towels until wide enough to fit securely in the MRI probe. 
The agarose used for these phantoms was expensive and could not be removed or re-used, thus a 
new phantom had to be made for every experiment. A new “green” phantom was designed to 
eliminate the need to re-make phantoms. This is a guide on how the “green” phantom was 





The phantom had to meet the following criteria: 
- Must be re-usable 
- Must hold a several 3-mm or 5-mm NMR tubes 
- Must incorporate a way to distinguish among NMR tubes in MR images 
The first phantom design was made to be a single solid piece to be printed with a 3D printer 
(Figure AC-1). The phantom could hold four 5-mm NMR tubes. Hollow slits were positioned 
around the tube and could be filled with a contrast agent so that the solutions in each tube could 
be differentiated in an MR image.  
 




When the original phantom was created it was determined that the plastic material used in 
the 3D printer was porous and could not hold any liquid contrast agent (Figure AC-3). Further, 
the holes for the NMR tubes were too small to fit NMR tubes and the body of the phantom was 
too big to fit into the probe. This phantom taught us many lessons. We realized that 






The final phantom design incorporated pieces made from a 3D printer and laser cutter. 
Instead of being a solid piece, the phantom was made of a hollow outer-casing (Figure AC-4) 
and an NMR tube holder made of interchangeable pieces (Figure AC-5).  
Figure AC-2. Original phantom design. 






The outer-casing was designed by modifying the structure of the original phantom made. 
Several short (~3 cm) hollow rings of different sizes were then printed to ensure that the 
phantom would have the correct diameter to fit snugly into the MRI probe. Once a size was 
determined, the entire outer-casing was printed with the 3D printer.  
The NMR tube holder shown in Figure AC-3 can hold eight 3-mm NMR tubes where one 
Figure AC-4. Outer-casing of phantom. 
Figure AC-5. Assembled NMR tube holder displayed on SolidWorks 
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tube can be placed outside of the ring and act as a marker. The inner pieces were designed such 
that the disks could be modified to hold a different number or type of NMR tubes. Again, pieces 
of different sizes had to be cut to determine which size allowed all the pieces to fit snugly 
together.  
Table AC-1. Images of the final phantom: 





Outer-casing (above) and NMR tube 





Outer-casing (right) and NMR tube 





NMR tube holder halfway inserted into 
outer-casing with a 3-mm NMR tube 
 
 
NMR tube holder completely inserted 




When imaged, the solutions inside the NMR tubes were all visible and the tube 
positioned outside of the ring of tubes served as a marker (Figure AB-6). 
       
 
The design and creation of a “green” MRI phantom was successful. The new phantom is 





A sheet of Delrin, a general-purpose thermoplastic, was selected based on desired 
thickness (1/8” Delrin was used for all phantom pieces). Phantom designs were made on 
SolidWorks, 3D CAD design software, and drawn as flat images. These images were then 
converted into .PDF format and transferred to a computer connected to the laser printer. On this 
computer, CorelDrawX3, a graphic design program, was used to make the outline of all the 
shapes red so that the laser printer could identify which regions to cut. The red image was then 
transferred to Trotec Job Control 7.4.9, a laser cutter program. The sheet of Delrin was placed 
into the Trotec Speedy 300 ™ laser cutter. After the laser was calibrated with the computer and 
laser-setting were selected (P:100%, f=10,000; V=1.0), the pieces were cut. 
3D Printer 
A Dimension 1200es 3D printer was used to create pieces of the phantom that could not 
be made with the laser cutter. These pieces were designed on SolidWorks and then transferred to 
Catalyst EX, a 3D printer program, which printed the design with ABS plastic. 
 
 
Figure AC-6. Magnetic resonance image of the final 
phantom holding seven NMR tubes that contain different 
concentrations of contrast agent 
 
